BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099. [PMID: 10382692 DOI: 10.1016/s0140-6736(98)08468-2] [Cited by in Crossref: 1126] [Cited by in F6Publishing: 976] [Article Influence: 46.9] [Reference Citation Analysis]
Number Citing Articles
1 Huang M, Prayson RA, Li Y. Genvoya-Associated and Simvastatin-Associated Noninflammatory and Nonautoimmune Myopathy: A Case Report and Literature Review. Journal of Clinical Neuromuscular Disease 2022;24:75-79. [DOI: 10.1097/cnd.0000000000000386] [Reference Citation Analysis]
2 Vuong E, Peer N, Chirwa E, Mhlongo S, Lombard C, Hemmings S, Kengne AP, Abrahams N, Seedat S. Prospective Association of Circulating Adipokines with Cardiometabolic Risk Profile Among Women: The Rape Impact Cohort Evaluation Study. Womens Health Rep (New Rochelle) 2022;3:820-33. [PMID: 36340478 DOI: 10.1089/whr.2022.0069] [Reference Citation Analysis]
3 Civeira F, Arca M, Cenarro A, Hegele RA. A mechanism-based operational definition and classification of hypercholesterolemia. Journal of Clinical Lipidology 2022. [DOI: 10.1016/j.jacl.2022.09.006] [Reference Citation Analysis]
4 Iacob SA, Iacob DG. Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients – a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown. Front Endocrinol 2022;13:814209. [DOI: 10.3389/fendo.2022.814209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Cicero AF, Cincione IR. Secondary (acquired) hypercholesterolemia. Cholesterol 2022. [DOI: 10.1016/b978-0-323-85857-1.00016-x] [Reference Citation Analysis]
6 Ghosh AJ, Sarkar S, Ghosh S, Saha T. Prebiotic Immunomodulators to Enhance Mucosal Immunity and to Reduce Mass Use of Antibiotics. Alternatives to Antibiotics 2022. [DOI: 10.1007/978-981-19-1854-4_17] [Reference Citation Analysis]
7 Furtado P, Soares LR, Duarte AJS, Casseb J. Self-Corporal Image among People Living with HIV/AIDS with Lipodystrophy Syndrome in Brazil. WJA 2022;12:32-42. [DOI: 10.4236/wja.2022.121003] [Reference Citation Analysis]
8 Armstrong DL. Chapter 35: Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome. The APhA Complete Review for Pharmacy, 13th Edition 2022. [DOI: 10.21019/9781582123615.ch35] [Reference Citation Analysis]
9 Emond B, Rossi C, Côté-Sergent A, Bookhart B, Anderson D, Lefebvre P, Lafeuille MH, Donga P. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States. Curr Med Res Opin 2021;:1-26. [PMID: 34812097 DOI: 10.1080/03007995.2021.2007006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 O'Neil PJ, Stafford KA, Ryscavage PA. Assessing risk factors for hypertension in young adults with perinatally acquired HIV infection: A case-control study. HIV Med 2021. [PMID: 34725913 DOI: 10.1111/hiv.13199] [Reference Citation Analysis]
11 Tang B, Zhao W. Sliding Dynamics and Bifurcations of a Filippov System with Nonlinear Threshold Control. Int J Bifurcation Chaos 2021;31:2150214. [DOI: 10.1142/s021812742150214x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Lopez-Alvarenga JC, Martinez DA, Diaz-Badillo A, Morales LD, Arya R, Jenkinson CP, Curran JE, Lehman DM, Blangero J, Duggirala R, Mummidi S, Martinez RD. Association of HIV-1 Infection and Antiretroviral Therapy With Type 2 Diabetes in the Hispanic Population of the Rio Grande Valley, Texas, USA. Front Med (Lausanne) 2021;8:676979. [PMID: 34291061 DOI: 10.3389/fmed.2021.676979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Silva ASD, Cavalcanti MDSM, Belmont TFM, Ximenes RAA, Silva AVD, Nóbrega DND, Souza RDS, Farias ICC, do Ó KP, Vasconcelos LRS, Diniz GTN, Miranda-Filho DB. The 1G/1G+1G/2G Genotypes of MMP1 rs1799750 Are Associated with Higher Levels of MMP-1 and Are Both Associated with Lipodystrophy in People Living with HIV on Antiretroviral Therapy. AIDS Res Hum Retroviruses 2021;37:399-406. [PMID: 33587019 DOI: 10.1089/AID.2020.0237] [Reference Citation Analysis]
14 Desormais I, Harimenshi D, Niyongabo T, Lacroix P, Aboyans V, Preux PM. HIV clinical stages and lower extremity arterial disease among HIV infected outpatients in Burundi. Sci Rep 2021;11:8296. [PMID: 33859308 DOI: 10.1038/s41598-021-87862-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Santos ECMD, Florindo AA, Santos AV, Picone CM, Dias TG, Segurado AC. Multicomponent physical activity program to prevent body changes and metabolic disturbances associated with antiretroviral therapy and improve quality of life of people living with HIV: a pragmatic trial. Clinics (Sao Paulo) 2021;76:e2457. [PMID: 33787675 DOI: 10.6061/clinics/2021/e2457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 De Vincentis S, Tartaro G, Rochira V, Santi D. HIV and Sexual Dysfunction in Men. J Clin Med 2021;10:1088. [PMID: 33807833 DOI: 10.3390/jcm10051088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Poles J, Tiozzo E, Konefal J, Rodriguez A, Woolger JM, Lewis JE. The Effects of a Nutrition Education Program on Dietary Intake and Biomarkers in HIV+ Adults. American Journal of Lifestyle Medicine. [DOI: 10.1177/1559827620986790] [Reference Citation Analysis]
18 Chinaeke EE, Li M, Bookstaver B, Love BL, Li X, Reeder G, Lu K. Management of infection among Medicare beneficiaries with HIV/AIDS: risk of diabetes with protease inhibitors and associated racial disparities using big data approach. AIDS Care 2020. [DOI: 10.1080/09540121.2020.1840503] [Reference Citation Analysis]
19 Bruder-Nascimento T, Kress TC, Kennard S, Belin de Chantemèle EJ. HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor-Dependent Increases in NADPH Oxidase 1 (Nox1), C-C Chemokine Receptor Type 5 (CCR5), and Inflammation. J Am Heart Assoc 2020;9:e018074. [PMID: 33003981 DOI: 10.1161/JAHA.120.018074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
20 Ohuche IO, Chikani UN, Oyenusi EE, Onu JU, Oduwole A. Correlates of fasting blood glucose among children living with hiv in a Nigerian tertiary hospital: a cross-sectional study. BMC Pediatr 2020;20:458. [PMID: 33008390 DOI: 10.1186/s12887-020-02335-y] [Reference Citation Analysis]
21 Lin CA, Behrens PH, Paiement G, Hardy WD, Mirocha J, Rettig RL, Kiziah HL, Rudikoff AG, Hernandez Conte A. Metabolic factors and post-traumatic arthritis may influence the increased rate of surgical site infection in patients with human immunodeficiency virus following total hip arthroplasty. J Orthop Surg Res 2020;15:316. [PMID: 32787972 DOI: 10.1186/s13018-020-01827-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Teasdale CA, Hernandez C, Zerbe A, Chege D, Hawken M, El-Sadr WM. Changes in D-dimer after initiation of antiretroviral therapy in adults living with HIV in Kenya. BMC Infect Dis 2020;20:508. [PMID: 32664854 DOI: 10.1186/s12879-020-05213-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gebrie A, Sisay M, Gebru T. Dyslipidemia in HIV/AIDS infected patients on follow up at referral hospitals of Northwest Ethiopia: A laboratory-based cross-sectional study. Obesity Medicine 2020;18:100217. [DOI: 10.1016/j.obmed.2020.100217] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Lipshultz SE, Sasaki N, Thompson B, Eidem BW, Cheng I, Colan SD, O'Brien SE, Amdani S, Shearer WT, Orav EJ, Miller TL, Wilkinson JD. Left ventricular diastolic dysfunction in HIV-uninfected infants exposed in utero to antiretroviral therapy. AIDS 2020;34:529-37. [PMID: 31764073 DOI: 10.1097/QAD.0000000000002443] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
25 Shaaban AN, Dias SS, Muggli Z, Peleteiro B, Martins MRO. Risk of Readmission Among HIV Patients in Public Portuguese Hospitals: Longitudinal Multilevel Population-Based Study. Front Public Health 2020;8:15. [PMID: 32154201 DOI: 10.3389/fpubh.2020.00015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Sinha A, Feinstein M. Epidemiology, pathophysiology, and prevention of heart failure in people with HIV. Prog Cardiovasc Dis 2020;63:134-41. [PMID: 31987806 DOI: 10.1016/j.pcad.2020.01.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
27 Chang CY, Whitt K, Liu Z, Caldwell SH. The Liver and Insulin Resistance: The Important Convergence of Endocrinology and Hepatology. Contemporary Endocrinology 2020. [DOI: 10.1007/978-3-030-25057-7_13] [Reference Citation Analysis]
28 Sopeyin A, Zhou L, Li M, Barakat L, Paintsil E. Dysregulation of sterol regulatory element-binding protein 2 gene in HIV treatment-experienced individuals. PLoS One 2019;14:e0226573. [PMID: 31846498 DOI: 10.1371/journal.pone.0226573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Bardenheier BH, Phares CR, Simpson D, Gregg E, Cho P, Benoit S, Marano N. Trends in Chronic Diseases Reported by Refugees Originating from Burma Resettling to the United States from Camps Versus Urban Areas During 2009-2016. J Immigr Minor Health 2019;21:246-56. [PMID: 29761353 DOI: 10.1007/s10903-018-0749-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Alikhani A, Morin H, Matte S, Alikhani P, Tremblay C, Durand M. Association between lipodystrophy and length of exposure to ARTs in adult HIV-1 infected patients in Montreal. BMC Infect Dis 2019;19:820. [PMID: 31533648 DOI: 10.1186/s12879-019-4446-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
31 Sopeyin A, Zhou L, Li M, Barakat L, Paintsil E. Dysregulation of Sterol Regulatory Element-Binding Protein 2 Gene in HIV Treatment-Experienced Individuals.. [DOI: 10.1101/742486] [Reference Citation Analysis]
32 Pangmekeh PJ, Awolu MM, Gustave S, Gladys T, Cumber SN. Association between highly active antiretroviral therapy (HAART) and hypertension in persons living with HIV/AIDS at the Bamenda regional hospital, Cameroon. Pan Afr Med J 2019;33:87. [PMID: 31489065 DOI: 10.11604/pamj.2019.33.87.15574] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
33 Ikama SM, Ekoba-otende F, Makani J, Bokilo A, Ossibi-ibara B, Ondze-kafata LI, Ellenga-mbolla BF, Gombet TR, Kimbally-kaky SG. Global Cardiovascular Risk of the HIV Positive Patients Receiving Antiretroviral Therapy in Brazzaville. WJCD 2019;09:553-561. [DOI: 10.4236/wjcd.2019.98048] [Reference Citation Analysis]
34 Nandhini LP, Kamalanathan S, Sahoo J. Definition, Diagnostic Criteria, Screening, Diagnosis, and Classification of Diabetes and Categories of Glucose Intolerance. The Diabetes Textbook 2019. [DOI: 10.1007/978-3-030-11815-0_6] [Reference Citation Analysis]
35 Carrasco-Hernandez R, Jácome R, López Vidal Y, Ponce de León S. Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review. ILAR J 2017;58:343-58. [PMID: 28985316 DOI: 10.1093/ilar/ilx026] [Cited by in Crossref: 113] [Cited by in F6Publishing: 113] [Article Influence: 22.6] [Reference Citation Analysis]
36 Fazekas-Lavu M, Tonks KTT, Samaras K. Benchmarks of Diabetes Care in Men Living With Treated HIV-Infection: A Tertiary Center Experience. Front Endocrinol (Lausanne) 2018;9:634. [PMID: 30429826 DOI: 10.3389/fendo.2018.00634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
37 Cibrián-Ponce A, Sánchez-Alemán MA, García-Jiménez S, Pérez-Martínez E, Bernal-Fernández G, Castañon-Mayo M, Ávila-Jiménez L, Toledano-Jaimes CD. Changes in cardiovascular risk and clinical outcomes in a HIV/AIDS cohort study over a 1-year period at a specialized clinic in Mexico. Ther Clin Risk Manag 2018;14:1757-64. [PMID: 30288045 DOI: 10.2147/TCRM.S170536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
38 Pedro MN, Rocha GZ, Guadagnini D, Santos A, Magro DO, Assalin HB, Oliveira AG, Pedro RJ, Saad MJA. Insulin Resistance in HIV-Patients: Causes and Consequences. Front Endocrinol (Lausanne) 2018;9:514. [PMID: 30233499 DOI: 10.3389/fendo.2018.00514] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
39 Dimala CA, Blencowe H, Choukem SP. The association between antiretroviral therapy and selected cardiovascular disease risk factors in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One 2018;13:e0201404. [PMID: 30059546 DOI: 10.1371/journal.pone.0201404] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
40 Ford SM Jr, Simon Peter L, Berner P, Cook G, Vande Stouwe C, Dufour J, Bagby G, Nelson S, Molina PE. Differential contribution of chronic binge alcohol and antiretroviral therapy to metabolic dysregulation in SIV-infected male macaques. Am J Physiol Endocrinol Metab 2018;315:E892-903. [PMID: 30040479 DOI: 10.1152/ajpendo.00175.2018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
41 Li Q, Xiao Y. Global Dynamics of a Virus-Immune System with Virus-Guided Therapy and Saturation Growth of Virus. Mathematical Problems in Engineering 2018;2018:1-18. [DOI: 10.1155/2018/4710586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
42 Adal M, Howe R, Kassa D, Aseffa A, Petros B. Malnutrition and lipid abnormalities in antiretroviral naïve HIV-infected adults in Addis Ababa: A cross-sectional study. PLoS One 2018;13:e0195942. [PMID: 29672576 DOI: 10.1371/journal.pone.0195942] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
43 Samaras K. Endocrine and Metabolic Emergencies in HIV/AIDS. Endocrine and Metabolic Medical Emergencies 2018. [DOI: 10.1002/9781119374800.ch8] [Reference Citation Analysis]
44 McMahon CN, Petoumenos K, Hesse K, Carr A, Cooper DA, Samaras K. High rates of incident diabetes and prediabetes are evident in men with treated HIV followed for 11 years. AIDS 2018;32:451-9. [PMID: 29381559 DOI: 10.1097/QAD.0000000000001709] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
45 Korem M, Wallach T, Bursztyn M, Maayan S, Olshtain-Pops K. High Prevalence of Hypertension in Ethiopian and Non-Ethiopian HIV-Infected Adults. Int J Hypertens 2018;2018:8637101. [PMID: 29623220 DOI: 10.1155/2018/8637101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
46 Dimala CA, Kadia BM, Kemah BL, Tindong M, Choukem SP. Association between CD4 Cell Count and Blood Pressure and Its Variation with Body Mass Index Categories in HIV-Infected Patients. Int J Hypertens 2018;2018:1691474. [PMID: 29610680 DOI: 10.1155/2018/1691474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
47 Huang YM, Hong XZ, Xu JH, Luo JX, Mo HY, Zhao HL. Autoimmunity and dysmetabolism of human acquired immunodeficiency syndrome. Immunol Res 2016;64:641-52. [PMID: 26676359 DOI: 10.1007/s12026-015-8767-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
48 Jao J, Yu W, Patel K, Miller TL, Karalius B, Geffner ME, DiMeglio LA, Mirza A, Chen JS, Silio M, McFarland EJ, Van Dyke RB, Jacobson D; Pediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol (AMP) study. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study. HIV Med 2018;19:175-83. [PMID: 29159965 DOI: 10.1111/hiv.12566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
49 Husain NE, Noor SK, Elmadhoun WM, Almobarak AO, Awadalla H, Woodward CL, Mital D, Ahmed MH. Diabetes, metabolic syndrome and dyslipidemia in people living with HIV in Africa: Re-emerging challenges not to be forgotten. HIV AIDS (Auckl). 2017;9:193-202. [PMID: 29184449 DOI: 10.2147/hiv.s137974] [Cited by in Crossref: 13] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
50 Armstrong DL. Chapter 35: Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome. The APhA Complete Review for Pharmacy, 12th edition 2017. [DOI: 10.21019/9781582122816.ch35] [Reference Citation Analysis]
51 Njelekela M, Mpembeni R, Muhihi A, Ulenga N, Aris E, Kakoko D. Lipodystrophy among HIV-Infected Patients Attending Care and Treatment Clinics in Dar es Salaam. AIDS Res Treat 2017;2017:3896539. [PMID: 29158917 DOI: 10.1155/2017/3896539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
52 Feinstein MJ, Bogorodskaya M, Bloomfield GS, Vedanthan R, Siedner MJ, Kwan GF, Longenecker CT. Cardiovascular Complications of HIV in Endemic Countries. Curr Cardiol Rep 2016;18:113. [PMID: 27730474 DOI: 10.1007/s11886-016-0794-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
53 Bayard C, Ledergerber B, Flepp M, Lecompte T, Moulin E, Hoffmann M, Weber R, Staehelin C, Di Benedetto C, Fux CA, Tarr PE, Hasse B; Swiss HIV Cohort Study . Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. Open Forum Infect Dis 2017;4:ofx177. [PMID: 29026869 DOI: 10.1093/ofid/ofx177] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
54 Kobayashi N, Nakahara M, Oka M, Saeki K. Additional attention to combination antiretroviral therapy-related lipodystrophy. World J Virol 2017; 6(3): 49-52 [PMID: 28868242 DOI: 10.5501/wjv.v6.i3.49] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
55 Tang B, Xiao Y, Sivaloganathan S, Wu J. A piecewise model of virus-immune system with effector cell-guided therapy. Applied Mathematical Modelling 2017;47:227-48. [DOI: 10.1016/j.apm.2017.03.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
56 Carvalho AS, Osório Valente R, Almeida Morais L, Modas Daniel P, Sá Carvalho R, Ferreira L, Cruz Ferreira R. HIV and coronary disease – When secondary prevention is insufficient. Revista Portuguesa de Cardiologia (English Edition) 2017;36:569.e1-569.e8. [DOI: 10.1016/j.repce.2016.10.019] [Reference Citation Analysis]
57 Ravaud C, Paré M, Azoulay S, Dani C, Ladoux A. Impairment of the activin A autocrine loop by lopinavir reduces self-renewal of distinct human adipose progenitors. Sci Rep 2017;7:2986. [PMID: 28592814 DOI: 10.1038/s41598-017-02807-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
58 Ghehi C, Gabillard D, Moh R, Badje A, Kouamé GM, Oouttara E, Ahibo H, N'Takpé JB, Lecarrou J, Eholié SP, Anglaret X, Danel C. High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d'Ivoire. PLoS One 2017;12:e0177440. [PMID: 28582393 DOI: 10.1371/journal.pone.0177440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
59 Filippas-Ntekouan S, Liberopoulos E, Elisaf M. Lipid testing in infectious diseases: possible role in diagnosis and prognosis. Infection 2017;45:575-88. [PMID: 28484991 DOI: 10.1007/s15010-017-1022-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
60 Sacilotto LB, Pereira PCM, Manechini JPV, Papini SJ. Body Composition and Metabolic Syndrome Components on Lipodystrophy Different Subtypes Associated with HIV. J Nutr Metab 2017;2017:8260867. [PMID: 28540084 DOI: 10.1155/2017/8260867] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
61 Dimala CA, Blencowe H. Association between highly active antiretroviral therapy and selected cardiovascular disease risk factors in sub-Saharan Africa: a systematic review and meta-analysis protocol. BMJ Open 2017;7:e013353. [PMID: 28279997 DOI: 10.1136/bmjopen-2016-013353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
62 Kingston MA, Bowman CA. The investigation of patients with HIV infection: 10 years of progress. Int J STD AIDS 2001;12:1-7. [DOI: 10.1177/095646240101200101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
63 Alencastro PR, Barcellos NT, Wolff FH, Ikeda ML, Schuelter-Trevisol F, Brandão AB, Fuchs SC. People living with HIV on ART have accurate perception of lipodystrophy signs: a cross-sectional study. BMC Res Notes 2017;10:40. [PMID: 28086977 DOI: 10.1186/s13104-017-2377-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
64 Soepnel LM, Norris SA, Schrier VJ, Browne JL, Rijken MJ, Gray G, Klipstein-Grobusch K. The association between HIV, antiretroviral therapy, and gestational diabetes mellitus. AIDS 2017;31:113-25. [PMID: 27677165 DOI: 10.1097/QAD.0000000000001277] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
65 Yalamanchi S, Brown T, Dobs A. HIV Infection and Diabetes. Principles of Diabetes Mellitus 2017. [DOI: 10.1007/978-3-319-18741-9_38] [Reference Citation Analysis]
66 Bednasz C, Luque AE, Zingman BS, Fischl MA, Gripshover BM, Venuto CS, Gu J, Feng Z, DiFrancesco R, Morse GD, Ma Q. Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders. Curr Vasc Pharmacol 2016;14:280-7. [PMID: 26733388 DOI: 10.2174/1570161114666160106151652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
67 Kitagaki T, Sato T, Hirai J, Kimura D, Kakurai K, Fukumoto M, Tajiri K, Kobayashi T, Kida T, Kojima S, Ikeda T. A Case of Proliferative Diabetic Retinopathy with HIV Infection in Which HAART Possibly Influenced the Prognosis of Visual Function. Case Rep Ophthalmol 2016;7:239-44. [PMID: 27990117 DOI: 10.1159/000452789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Matoga MM, Hosseinipour MC, Aga E, Ribaudo HJ, Kumarasamy N, Bartlett J, Hughes MD; ACTG A5230 Study Team. Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings. Antivir Ther 2017;22:205-13. [PMID: 27740537 DOI: 10.3851/IMP3101] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
69 Dos Santos Ferreira R, de Cássia Avellaneda Guimarães R, Jardim Cury Pontes ER, Aragão do Nascimento V, Aiko Hiane P. The Effectiveness of a Bioactive Food Compound in the Lipid Control of Individuals with HIV/AIDS. Nutrients 2016;8:E598. [PMID: 27740592 DOI: 10.3390/nu8100598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
70 Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2015;38:1153-1168. [PMID: 26370106 DOI: 10.1007/s40264-015-0339-z] [Cited by in Crossref: 83] [Cited by in F6Publishing: 67] [Article Influence: 11.9] [Reference Citation Analysis]
71 Dirajlal-Fargo S, Moser C, Brown TT, Kelesidis T, Dube MP, Stein JH, Currier J, McComsey GA. Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s. Open Forum Infect Dis 2016;3:ofw174. [PMID: 27704026 DOI: 10.1093/ofid/ofw174] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
72 Abebe SM, Getachew A, Fasika S, Bayisa M, Girma Demisse A, Mesfin N. Diabetes mellitus among HIV-infected individuals in follow-up care at University of Gondar Hospital, Northwest Ethiopia. BMJ Open 2016;6:e011175. [PMID: 27540099 DOI: 10.1136/bmjopen-2016-011175] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
73 Agrawal N, Freitas Corradi P, Gumaste N, Goldberg IJ. Triglyceride Treatment in the Age of Cholesterol Reduction. Prog Cardiovasc Dis 2016;59:107-18. [PMID: 27544319 DOI: 10.1016/j.pcad.2016.08.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
74 Gomes A, Reyes EV, Garduno LS, Rojas R, Mir Mesejo G, Del Rosario E, Jose L, Javier C, Vaughan C, Donastorg Y, Hammer S, Brudney K, Taylor BS. Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy. PLoS One 2016;11:e0160797. [PMID: 27508301 DOI: 10.1371/journal.pone.0160797] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
75 Isa SE, Oche AO, Kang'ombe AR, Okopi JA, Idoko JA, Cuevas LE, Gill GV. Human Immunodeficiency Virus and Risk of Type 2 Diabetes in a Large Adult Cohort in Jos, Nigeria. Clin Infect Dis 2016;63:830-5. [PMID: 27307508 DOI: 10.1093/cid/ciw381] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
76 Ankrah AO, Glaudemans AWJM, Klein HC, Dierckx RAJO, Sathekge M. The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases. Nucl Med Mol Imaging 2017;51:127-39. [PMID: 28559937 DOI: 10.1007/s13139-016-0422-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
77 Dimala CA, Atashili J, Mbuagbaw JC, Wilfred A, Monekosso GL. A Comparison of the Diabetes Risk Score in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) and HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon. PLoS One 2016;11:e0155560. [PMID: 27195956 DOI: 10.1371/journal.pone.0155560] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
78 Dimala CA, Atashili J, Mbuagbaw JC, Wilfred A, Monekosso GL. Prevalence of Hypertension in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon. PLoS One 2016;11:e0148100. [PMID: 26862763 DOI: 10.1371/journal.pone.0148100] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
79 Yalamanchi S, Brown T, Dobs A. HIV Infection and Diabetes. Principles of Diabetes Mellitus 2016. [DOI: 10.1007/978-3-319-20797-1_38-1] [Reference Citation Analysis]
80 HIV protease inhibitors. Meyler's Side Effects of Drugs 2016. [DOI: 10.1016/b978-0-444-53717-1.01693-0] [Reference Citation Analysis]
81 Sekhar RV. Treatment of dyslipidemia in HIV. Curr Atheroscler Rep 2015;17:493. [PMID: 25702057 DOI: 10.1007/s11883-015-0493-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
82 Leach LL, Bassett SH, Smithdorf G, Andrews BS, Travill AL. A Systematic Review of the Effects of Exercise Interventions on Body Composition in HIV+ Adults. Open AIDS J 2015;9:66-79. [PMID: 26587075 DOI: 10.2174/1874613601509010066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
83 Sm M, A K, W G, A B, Ac O, Ba D, I K. Effect of Aerobic Exercise on CD4 Cell Count and Lipid Profile of HIV Infected Persons in North Eastern Nigeria. J AIDS Clin Res 2015;6:508. [PMID: 30918743 DOI: 10.4172/2155-6113.1000508] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
84 Stupin JH. Nicht mehr Gestationsdiabetes mit Proteasehemmern bei HIV. Info Diabetol 2015;9:20-21. [DOI: 10.1007/s15034-015-0627-9] [Reference Citation Analysis]
85 Maganga E, Smart LR, Kalluvya S, Kataraihya JB, Saleh AM, Obeid L, Downs JA, Fitzgerald DW, Peck RN. Glucose Metabolism Disorders, HIV and Antiretroviral Therapy among Tanzanian Adults. PLoS One 2015;10:e0134410. [PMID: 26287742 DOI: 10.1371/journal.pone.0134410] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
86 Aceti A, Gianserra L, Lambiase L, Pennica A, Teti E. Pharmacogenetics as a tool to tailor antiretroviral therapy: A review. World J Virology 2015; 4(3): 198-208 [PMID: 26279982 DOI: 10.5501/wjv.v4.i3.198] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
87 McIlleron H, Abdel-Rahman S, Dave JA, Blockman M, Owen A. Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research. J Infect Dis 2015;211 Suppl 3:S115-25. [PMID: 26009615 DOI: 10.1093/infdis/jiu600] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
88 Duran L, Rodriguez C, Drozd D, Nance RM, Delaney JA, Burkholder G, Mugavero MJ, Willig JH, Warriner AH, Crane PK, Atkinson BE, Harrington RD, Dhanireddy S, Saag MS, Kitahata MM, Crane HM. Fructosamine and Hemoglobin A1c Correlations in HIV-Infected Adults in Routine Clinical Care: Impact of Anemia and Albumin Levels. AIDS Res Treat 2015;2015:478750. [PMID: 26273478 DOI: 10.1155/2015/478750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
89 Xu D, Sun L. Role of microRNA biogenesis in adipocyte and lipodystrophy. Adipocyte 2015;4:222-4. [PMID: 26257995 DOI: 10.1080/21623945.2014.995507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
90 Lai S, Fishman EK, Lai H, Moore R, Cofrancesco J Jr, Pannu H, Tong W, Du J, Barlett J. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. Clin Infect Dis 2008;46:600-10. [PMID: 19641630 DOI: 10.1086/526782] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
91 Vance DE, Fazeli PL, Dodson JE, Ackerman M, Talley M, Appel SJ. The synergistic effects of HIV, diabetes, and aging on cognition: implications for practice and research. J Neurosci Nurs 2014;46:292-305. [PMID: 25099061 DOI: 10.1097/JNN.0000000000000074] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
92 Zhou DT, Kodogo V, Chokuona KF, Gomo E, Oektedalen O, Stray-Pedersen B. Dyslipidemia and cardiovascular disease risk profiles of patients attending an HIV treatment clinic in Harare, Zimbabwe. HIV AIDS (Auckl) 2015;7:145-55. [PMID: 25999764 DOI: 10.2147/HIV.S78523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
93 Cunha JD, Maselli LMF, Stern ACB, Spada C, Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World J Virology 2015; 4(2): 56-77 [PMID: 25964872 DOI: 10.5501/wjv.v4.i2.56] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 83] [Article Influence: 9.8] [Reference Citation Analysis]
94 Harris V, Samaras K. Diabetes in treated hepatitis C infection: dodging the sweet sting. Diabetes Management 2015;5:155-159. [DOI: 10.2217/dmt.15.5] [Reference Citation Analysis]
95 Gleason RL Jr, Caulk AW, Seifu D, Parker I, Vidakovic B, Getenet H, Assefa G, Amogne W. Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia. PLoS One 2015;10:e0117125. [PMID: 25915208 DOI: 10.1371/journal.pone.0117125] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
96 Chastain DB, Henderson H, Stover KR. Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J 2015;9:23-37. [PMID: 25866592 DOI: 10.2174/1874613601509010023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
97 Szczerkowska-Dobosz A, Olszewska B, Lemańska M, Purzycka-Bohdan D, Nowicki R. Acquired facial lipoatrophy: pathogenesis and therapeutic options. Postepy Dermatol Alergol 2015;32:127-33. [PMID: 26015783 DOI: 10.5114/pdia.2014.40971] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
98 Ma X, Lee P, Chisholm DJ, James DE. Control of adipocyte differentiation in different fat depots; implications for pathophysiology or therapy. Front Endocrinol (Lausanne) 2015;6:1. [PMID: 25688231 DOI: 10.3389/fendo.2015.00001] [Cited by in Crossref: 48] [Cited by in F6Publishing: 63] [Article Influence: 6.0] [Reference Citation Analysis]
99 Yahiaoui A, Voss JG. Exercise and Management of Body Weight in Older People Living with HIV. Health of HIV Infected People 2015. [DOI: 10.1016/b978-0-12-800767-9.00017-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
100 Chapter 35. Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome. The APhA Complete Review for Pharmacy, 11th Edition 2015. [DOI: 10.21019/9781582122175.ch35] [Reference Citation Analysis]
101 Osime OE, Ese-Onakewhor JU, Kolade SO. Fibrinolytic changes in pregnant women on highly active antiretroviral therapy. Saudi Med J 2015;36:200-3. [PMID: 25719585 DOI: 10.15537/smj.2015.2.10372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
102 Monteiro JP, Salomão RG. Heterogeneity in Nutritional and Lipid Profiles in Children and Adolescents with Human Immunodeficiency Virus Treated with Highly Active Antiretroviral Therapy. Health of HIV Infected People 2015. [DOI: 10.1016/b978-0-12-800769-3.00022-6] [Reference Citation Analysis]
103 Hejazi N, Rajikan R. Metabolic Abnormalities in HIV-Infected Populations without or with Antiretroviral Therapy (ART). Health of HIV Infected People 2015. [DOI: 10.1016/b978-0-12-800769-3.00002-0] [Reference Citation Analysis]
104 Mcmahon CN, Blanchard E, Samaras K. Diabetes and Dyslipidemia in Treated Human Immunodeficiency Virus Infection and Approaches for Cardiometabolic Care. Health of HIV Infected People 2015. [DOI: 10.1016/b978-0-12-800769-3.00024-x] [Reference Citation Analysis]
105 Lee FJ, Carr A. Dyslipidemia in HIV-Infected Patients. Dyslipidemias 2015. [DOI: 10.1007/978-1-60761-424-1_9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
106 Singh V, Watson RR. Effects of Omega-3 Fatty Acids on Body Composition and Health in HIV/AIDS During HAART Therapy. Health of HIV Infected People 2015. [DOI: 10.1016/b978-0-12-800769-3.00005-6] [Reference Citation Analysis]
107 Rai P, Singh T, Lederman R, Chawla A, Kumar D, Cheng K, Valecha G, Mathieson PW, Saleem MA, Malhotra A, Singhal PC. Hyperglycemia enhances kidney cell injury in HIVAN through down-regulation of vitamin D receptors. Cell Signal 2015;27:460-9. [PMID: 25542307 DOI: 10.1016/j.cellsig.2014.12.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
108 Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26-39. [PMID: 23963694 DOI: 10.1007/s13181-013-0325-8] [Cited by in Crossref: 214] [Cited by in F6Publishing: 224] [Article Influence: 23.8] [Reference Citation Analysis]
109 Gomo ZA, Hakim JG, Walker SA, Tinago W, Mandozana G, Kityo C, Munderi P, Katabira E, Reid A, Gibb DM, Gilks CF; DART Team. Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study. AIDS Res Ther 2014;11:32. [PMID: 25320632 DOI: 10.1186/1742-6405-11-32] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
110 Itinoseki Kaio DJ, Rondó PH, Luzia LA, Souza JM, Firmino AV, Santos SS. Vitamin E concentrations in adults with HIV/AIDS on highly active antiretroviral therapy. Nutrients 2014;6:3641-52. [PMID: 25225815 DOI: 10.3390/nu6093641] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
111 Leyes P, Martínez E, Larrousse M, Cofán M, Trabal J, Pérez-Heras AM, Forga MT, Ros E. Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial. BMC Infect Dis 2014;14:497. [PMID: 25209653 DOI: 10.1186/1471-2334-14-497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
112 Duracinsky M, Leclercq P, Herrmann S, Christen MO, Dolivo M, Goujard C, Chassany O. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis 2014;14:474. [PMID: 25178390 DOI: 10.1186/1471-2334-14-474] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
113 Semu H, Zack RM, Liu E, Hertzmark E, Spiegelman D, Sztam K, Hawkins C, Chalamila G, Muya A, Siril H, Mwiru R, Mtasiwa D, Fawzi W. Prevalence and Risk Factors for Overweight and Obesity among HIV-Infected Adults in Dar es Salaam, Tanzania. J Int Assoc Provid AIDS Care 2016;15:512-21. [PMID: 25146972 DOI: 10.1177/2325957414542574] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
114 Anand D, Puri S. Anthropometric and Nutritional Profile of People Living with HIV and AIDS in India: an Assessment. Indian J Community Med 2014;39:161-8. [PMID: 25136157 DOI: 10.4103/0970-0218.137153] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
115 Sasson SC, Kelleher AD. Site-specific host gene modification by zinc finger nucleases: pointing the way to drug free control of HIV-1? Clin Transl Immunology 2014;3:e19. [PMID: 25505967 DOI: 10.1038/cti.2014.12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
116 Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Melbourne KM, Ha B, McComsey GA. Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS 2014;28:1451-61. [PMID: 24637543 DOI: 10.1097/QAD.0000000000000266] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
117 Godoy-Santos AL, Bordalo-Rodrigues M, Rosemberg L, Fernandes TD, Lima AL, Camanho GL, Maffulli N. Kager's fat pad inflammation associated with HIV infection and AIDS: MRI findings. Skeletal Radiol 2014;43:1257-62. [PMID: 25027638 DOI: 10.1007/s00256-014-1931-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
118 Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52:815-831. [PMID: 23703578 DOI: 10.1007/s40262-013-0075-4] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 11.3] [Reference Citation Analysis]
119 Guaraldi G, Stentarelli C, Zona S, Santoro A. HIV-associated lipodystrophy: impact of antiretroviral therapy. Drugs 2013;73:1431-50. [PMID: 24002702 DOI: 10.1007/s40265-013-0108-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
120 Ferrando SJ, Loftus T. Mood Disorders, Delirium, and Other Neurobehavioral Symptoms and Disorders in the HAART Era. The Spectrum of Neuro-AIDS Disorders 2014. [DOI: 10.1128/9781555815691.ch28] [Reference Citation Analysis]
121 Goodkin K, Aronow A, Baldwin G, Molina R, Zheng W, David Hardy W. HIV-1-Associated Neurocognitive Disorders in the HAART Era. The Spectrum of Neuro-AIDS Disorders 2014. [DOI: 10.1128/9781555815691.ch1] [Reference Citation Analysis]
122 Palacios R, Santos J, Camino X, Arazo P, Torres Perea R, Echevarrfa S, Ribera E, Sánchez de la Rosa R, Moreno Guillen S; Recover Study Group. Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Curr Ther Res Clin Exp 2005;66:117-29. [PMID: 24672118 DOI: 10.1016/j.curtheres.2005.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
123 Gwee A, Cranswick N. Anti-infective use in children and pregnancy: current deficiencies and future challenges. Br J Clin Pharmacol 2015;79:216-21. [PMID: 24588467 DOI: 10.1111/bcp.12363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
124 Ssinabulya I, Kayima J, Longenecker C, Luwedde M, Semitala F, Kambugu A, Ameda F, Bugeza S, McComsey G, Freers J, Nakanjako D. Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda. PLoS One 2014;9:e89537. [PMID: 24586854 DOI: 10.1371/journal.pone.0089537] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
125 Jeong SJ, Kim HW, Ku NS, Han SH, Kim CO, Choi JY, Song YG, Kim JM. Clinical factors associated with carotid plaque and intima-medial thickness in HIV-infected patients. Yonsei Med J 2013;54:990-8. [PMID: 23709436 DOI: 10.3349/ymj.2013.54.4.990] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
126 Dragović G, Malović D, Jevtović Đ. Metabolic syndrome and combined highly active antiretroviral therapy. Medicinska istraživanja 2014;48:24-31. [DOI: 10.5937/medist1401024d] [Reference Citation Analysis]
127 Hernandez-Vallejo SJ, Beaupere C, Larghero J, Capeau J, Lagathu C. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell 2013;12:955-65. [PMID: 23795945 DOI: 10.1111/acel.12119] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 5.5] [Reference Citation Analysis]
128 Ngala RA, Fianko K. Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis. Afr Health Sci 2013;13:1107-16. [PMID: 24940339 DOI: 10.4314/ahs.v13i4.35] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
129 Alonso-Basanta M, Fang P, Maity A, Hahn SM, Lustig RA, Dorsey JF. A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. J Neurooncol 2014;116:365-72. [PMID: 24194293 DOI: 10.1007/s11060-013-1303-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
130 Abraham AG, Li X, Jacobson LP, Estrella MM, Evans RW, Witt MD, Phair J. Antiretroviral therapy-induced changes in plasma lipids and the risk of kidney dysfunction in HIV-infected men. AIDS Res Hum Retroviruses 2013;29:1346-52. [PMID: 23758574 DOI: 10.1089/AID.2012.0253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
131 Reyskens KM, Fisher TL, Schisler JC, O'Connor WG, Rogers AB, Willis MS, Planesse C, Boyer F, Rondeau P, Bourdon E, Essop MF. Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir). PLoS One 2013;8:e73347. [PMID: 24098634 DOI: 10.1371/journal.pone.0073347] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
132 Lai S, Fishman EK, Gerstenblith G, Brinker J, Tai H, Chen S, Li J, Tong W, Detrick B, Lai H. Vitamin D deficiency is associated with coronary artery calcification in cardiovascularly asymptomatic African Americans with HIV infection. Vasc Health Risk Manag 2013;9:493-500. [PMID: 24009422 DOI: 10.2147/VHRM.S48388] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
133 Muhammad S, Sani MU, Okeahialam BN. Cardiovascular disease risk factors among HIV-infected Nigerians receiving highly active antiretroviral therapy. Niger Med J. 2013;54:185-190. [PMID: 23901181 DOI: 10.4103/0300-1652.114591] [Cited by in Crossref: 29] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
134 Sathekge M, Van de Wiele C, Signore A. Nuclear Medicine Imaging of Tuberculosis and Human Immunodeficiency Virus. Diagnostic Imaging of Infections and Inflammatory Diseases 2013. [DOI: 10.1002/9781118484388.ch15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
135 Bajaj S, Tyagi SK, Bhargava A. Metabolic syndrome in human immunodeficiency virus positive patients. Indian J Endocrinol Metab 2013;17:117-20. [PMID: 23776863 DOI: 10.4103/2230-8210.107821] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
136 Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi E, Wood K, Holmberg SD, Brooks JT; HOPS Investigators. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chronic Dis 2013;10:E10. [PMID: 23347705 DOI: 10.5888/pcd10.120083] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
137 Patel SM, Thames AD, Arbid N, Panos SE, Castellon S, Hinkin CH. The aggregate effects of multiple comorbid risk factors on cognition among HIV-infected individuals. J Clin Exp Neuropsychol 2013;35:421-34. [PMID: 23547924 DOI: 10.1080/13803395.2013.783000] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
138 Vu CN, Ruiz-Esponda R, Yang E, Chang E, Gillard B, Pownall HJ, Hoogeveen RC, Coraza I, Balasubramanyam A. Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients. Metabolism 2013;62:1014-20. [PMID: 23522788 DOI: 10.1016/j.metabol.2013.01.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
139 Denue BA, Alkali MB, Abjah AU, Kida IM, Ajayi B, Fate BZ. Changes in Lipid Profiles and Other Biochemical Parameters in HIV-1 Infected Patients Newly Commenced on HAART Regimen. Infect Dis (Auckl) 2013;6:7-14. [PMID: 24847172 DOI: 10.4137/IDRT.S10044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
140 Hsu MC, Chang CS, Lee KT, Sun HY, Tsai YS, Kuo PH, Young KC, Wu CH. Central obesity in males affected by a dyslipidemia-associated genetic polymorphism on APOA1/C3/A4/A5 gene cluster. Nutr Diabetes 2013;3:e61. [PMID: 23459084 DOI: 10.1038/nutd.2013.2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
141 Nila A, Setiawati HI, Andrajati R, Djauzi S. Evaluation of side effects events peripheral neuropathy and lipodystrophy in patients with HIV/AIDS who used stavudine in antiretroviral regimens. HIV & AIDS Review 2013;12:4-8. [DOI: 10.1016/j.hivar.2013.02.002] [Reference Citation Analysis]
142 Souza SJ, Luzia LA, Santos SS, Carvalho Rondó PH. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Revista da Associação Médica Brasileira (English Edition) 2013;59:186-198. [DOI: 10.1016/s2255-4823(13)70454-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
143 Biron A, Bobin-Dubigeon C, Volteau C, Piroth L, Perré P, Leport C, Prazuck T, Jovelin T, Billard M, Sébille V, Bard JM, Raffi F, Biron C. Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy. AIDS Res Hum Retroviruses 2012;28:1672-8. [PMID: 22731114 DOI: 10.1089/AID.2012.0048] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
144 Mandina Ndona M, Longo-Mbenza B, Wumba R, Tandu Umba B, Buassa-Bu-Tsumbu B, Mbula Mambimbi M, Wobin TO, Mbungu Fuele S. Nadir CD4+, religion, antiretroviral therapy, incidence of type 2 diabetes mellitus, and increasing rates of obesity among black Africans with HIV disease. Int J Gen Med 2012;5:983-90. [PMID: 23226071 DOI: 10.2147/IJGM.S32167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
145 Feeney ER, van Vonderen MG, Wit F, Danner SA, van Agtmael MA, Villarroya F, Domingo P, Capeau J, Reiss P, Mallon PW; MEDICLAS, NECATT study groups. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA. AIDS 2012;26:2165-74. [PMID: 22874517 DOI: 10.1097/QAD.0b013e328358b279] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
146 Sinxadi PZ, McIlleron HM, Dave JA, Smith PJ, Levitt NS, Maartens G. Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study. AIDS Res Ther 2012;9:32. [PMID: 23098156 DOI: 10.1186/1742-6405-9-32] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
147 Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Int AIDS Soc 2012;15:17426. [PMID: 23078769 DOI: 10.7448/IAS.15.2.17426] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
148 Pan J, Mott M, Xi B, Hepner E, Guan M, Fousek K, Magnusson R, Tinsley R, Valdes F, Frankel P, Synold T, Chow WA. Phase I study of nelfinavir in liposarcoma. Cancer Chemother Pharmacol 2012;70:791-9. [PMID: 22983015 DOI: 10.1007/s00280-012-1961-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
149 Freitas P, Carvalho D, Santos AC, Mesquita J, Matos MJ, Madureira AJ, Martinez E, Sarmento A, Medina JL. Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance. BMC Infect Dis 2012;12:180. [PMID: 22866963 DOI: 10.1186/1471-2334-12-180] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
150 Piloya T, Bakeera-Kitaka S, Kekitiinwa A, Kamya MR. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. J Int AIDS Soc 2012;15:17427. [PMID: 22814353 DOI: 10.7448/IAS.15.2.17427] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
151 Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, Hasson H, Guffanti M, Gianotti N, Bigoloni A, Lazzarin A, Castagna A. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol 2012;27:657-65. [PMID: 22722952 DOI: 10.1007/s10654-012-9707-5] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 4.9] [Reference Citation Analysis]
152 Alam N, Cortina-Borja M, Goetghebuer T, Marczynska M, Vigano A, Thorne C; European Paediatric HIV and Lipodystrophy Study Group in EuroCoord. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr 2012;59:314-24. [PMID: 22205436 DOI: 10.1097/QAI.0b013e31824330cb] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
153 Godoi ETAM, Brandt CT, Godoi JTAM, Lacerda HR, Albuquerque VMGD, Zirpoli JC, Godoi JTAM, Sarteschi C. Efeito da terapia antirretroviral e dos níveis de carga viral no complexo médio-intimal e no índice tornozelo-braço em pacientes infectados pelo HIV. J vasc bras 2012;11:123-131. [DOI: 10.1590/s1677-54492012000200009] [Reference Citation Analysis]
154 Holt JL, Kraft-Terry SD, Chang L. Neuroimaging studies of the aging HIV-1-infected brain. J Neurovirol 2012;18:291-302. [PMID: 22653528 DOI: 10.1007/s13365-012-0114-1] [Cited by in Crossref: 95] [Cited by in F6Publishing: 86] [Article Influence: 8.6] [Reference Citation Analysis]
155 Nazih H, Raffi F, Taïeb A, Reynes J, Choutet P, Cassuto JP, Ferry T, Chêne G, Leport C, Bard JM; Aproco-Copilote Anrs Co 08 Study Group. Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: the ANRS CO8 APROCO-COPILOTE study. AIDS Res Hum Retroviruses 2012;28:393-9. [PMID: 21877956 DOI: 10.1089/aid.2010.0311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
156 Lai H, Gerstenblith G, Fishman EK, Brinker J, Kickler T, Tong W, Bhatia S, Hong T, Chen S, Li J, Detrick B, Lai S. Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection. Clin Infect Dis 2012;54:1747-55. [PMID: 22423137 DOI: 10.1093/cid/cis306] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
157 Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs 2011;71:1071-91. [PMID: 21668043 DOI: 10.2165/11202240-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
158 Rauso R, Gherardini G, Parlato V, Amore R, Tartaro G. Polyacrylamide gel for facial wasting rehabilitation: how many milliliters per session? Aesthetic Plast Surg 2012;36:174-9. [PMID: 21638162 DOI: 10.1007/s00266-011-9757-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
159 Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, Protopopescu C, Leport C, Raffi F, Chêne G; ANRS CO8 APROCO-COPILOTE Cohort Study Group. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012;26:303-14. [PMID: 22089377 DOI: 10.1097/QAD.0b013e32834e8776] [Cited by in Crossref: 166] [Cited by in F6Publishing: 176] [Article Influence: 15.1] [Reference Citation Analysis]
160 Gasparotto AS, Sprinz E, Lazzaretti RK, Kuhmmer R, Silveira JM, Basso RP, Pinheiro CA, Silveira MF, Ribeiro JP, Mattevi VS. Genetic polymorphisms in estrogen receptors and sexual dimorphism in fat redistribution in HIV-infected patients on HAART. AIDS 2012;26:19-26. [PMID: 22011627 DOI: 10.1097/QAD.0b013e32834db3ac] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
161 Guaraldi G, Chiara S, Zona S, Bagni B. Anthropometry in the Assessment of HIV-Related Lipodystrophy. Handbook of Anthropometry 2012. [DOI: 10.1007/978-1-4419-1788-1_152] [Reference Citation Analysis]
162 Rees TD. Pathology and Management of Periodontal Problems in Patients with HIV Infection. Carranza's Clinical Periodontology 2012. [DOI: 10.1016/b978-1-4377-0416-7.00019-6] [Reference Citation Analysis]
163 Hazany S, Rojas R, Moonis G. Lipodystrophy of HIV (LDHIV) in the Head and Neck: Imaging and Clinical Features. IJOHNS 2012;01:24-27. [DOI: 10.4236/ijohns.2012.12005] [Reference Citation Analysis]
164 Ihenetu K, Mason D. Biochemical Manifestation of HIV Lipodystrophy Syndrome. Int J MCH AIDS 2012;1:92-101. [PMID: 27621962 DOI: 10.21106/ijma.6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
165 Nelson L, Stewart KJ. Autologous Fat Transfer for HIV-Associated Facial Lipodystrophy. Advanced Surgical Facial Rejuvenation 2012. [DOI: 10.1007/978-3-642-17838-2_63] [Reference Citation Analysis]
166 Anjos EM, Pfrimer K, Machado AA, Cunha SF, Salomão RG, Monteiro JP. Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up. Clinics (Sao Paulo) 2011;66:407-10. [PMID: 21552663 DOI: 10.1590/s1807-59322011000300007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
167 Ferrer E, del Rio L, Martínez E, Curto J, Domingo P, Ribera E, Negredo E, Rosales J, Saumoy M, Ordóñez J, Gatell JM, Podzamczer D. Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. AIDS Res Hum Retroviruses 2011;27:1061-5. [PMID: 21166602 DOI: 10.1089/AID.2010.0254] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
168 Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS 2011;6:266-71. [PMID: 21546831 DOI: 10.1097/COH.0b013e328347876c] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 6.3] [Reference Citation Analysis]
169 Freitas P, Carvalho D, Souto S, Santos AC, Xerinda S, Marques R, Martinez E, Sarmento A, Medina JL. Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients. BMC Infect Dis 2011;11:246. [PMID: 21933422 DOI: 10.1186/1471-2334-11-246] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
170 Faurholt-Jepsen D, Range N, Praygod G, Jeremiah K, Faurholt-Jepsen M, Aabye MG, Changalucha J, Christensen DL, Pipper CB, Krarup H, Witte DR, Andersen AB, Friis H. Diabetes is a risk factor for pulmonary tuberculosis: a case-control study from Mwanza, Tanzania. PLoS One 2011;6:e24215. [PMID: 21912626 DOI: 10.1371/journal.pone.0024215] [Cited by in Crossref: 70] [Cited by in F6Publishing: 82] [Article Influence: 5.8] [Reference Citation Analysis]
171 van Wijk JP, Cabezas MC. Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. Int J Vasc Med 2012;2012:201027. [PMID: 21876813 DOI: 10.1155/2012/201027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
172 Gopal M, Bhaskaran A, Khalife WI, Barbagelata A. Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem. Curr Cardiol Rev 2009;5:149-54. [PMID: 20436855 DOI: 10.2174/157340309788166705] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
173 Freitas P, Carvalho D, Santos AC, Mesquita J, Correia F, Xerinda S, Marques R, Martinez E, Sarmento A, Medina JL. Assessment of body fat composition disturbances by bioimpedance analysis in HIV-infected adults. J Endocrinol Invest 2011;34:e321-9. [PMID: 21737998 DOI: 10.3275/7841] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
174 Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, Xu X, Lievano F, Lehman HP, Mast TC, Nguyen BY. Long-term safety from the raltegravir clinical development program. Curr HIV Res 2011;9:40-53. [PMID: 21198432 DOI: 10.2174/157016211794582650] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
175 Bruno CB, Schapiro JM, Saberi P. An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature. J Int Assoc Physicians AIDS Care (Chic) 2011;10:219-22. [PMID: 21518854 DOI: 10.1177/1545109711404945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
176 Mynarcik DC, Mcnurlan MA, Melendez MM, Vosswinkel JA, Gelato MC. Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance. Pathology Research International 2011;2011:1-8. [DOI: 10.4061/2011/736425] [Reference Citation Analysis]
177 Feeney ER, Mallon PW. HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J 2011;5:49-63. [PMID: 21643501 DOI: 10.2174/1874192401105010049] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 8.0] [Reference Citation Analysis]
178 Veloso S, Olona M, Peraire J, Viladés C, Pardo P, Domingo P, Asensi V, Broch M, Aguilar C, López-Dupla M, Aragonés G, Garcia-Pardo G, Sirvent JJ, Vendrell J, Richart C, Vidal F; Hiv Lipodystrophy Study Group. No relationship between TNF-α genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: a case-control study and a meta-analysis. AIDS Res Hum Retroviruses 2011;27:143-52. [PMID: 20854131 DOI: 10.1089/aid.2009.0312] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
179 Goldhaber-Fiebert JD, Jeon CY, Cohen T, Murray MB. Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. Int J Epidemiol 2011;40:417-28. [PMID: 21252210 DOI: 10.1093/ije/dyq238] [Cited by in Crossref: 65] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
180 Lamiraud K, Moatti J, Raffi F, Maria-patrizia C, Protopopescu C, Michelet C, Luminita S, Fideline C, Catherine L, Bruno S. Adherence to and Effectiveness of Highly Active Antiretroviral Treatment for HIV Infection: Assessing the Bidirectional Relationship. SSRN Journal. [DOI: 10.2139/ssrn.2332037] [Reference Citation Analysis]
181 Gil del Valle L. Pathophysiological Implications of Altered Redox Balance in HIV/AIDS Infection: Diagnosis and Counteract Interventions. ACS Symposium Series 2011. [DOI: 10.1021/bk-2011-1083.ch002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
182 Manda KR, Banerjee A, Banks WA, Ercal N. Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. Free Radic Biol Med 2011;50:801-10. [PMID: 21193030 DOI: 10.1016/j.freeradbiomed.2010.12.029] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
183 Martí-carvajal AJ, Cruciani M. Pharmacological interventions for treating dyslipidemia in patients with HIV infection. Cochrane Database of Systematic Reviews 2010. [DOI: 10.1002/14651858.cd008869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
184 Wilk A, Urbanska K, Yang S, Wang JY, Amini S, Del Valle L, Peruzzi F, Meggs L, Reiss K. Insulin-like growth factor-I-forkhead box O transcription factor 3a counteracts high glucose/tumor necrosis factor-α-mediated neuronal damage: implications for human immunodeficiency virus encephalitis. J Neurosci Res. 2011;89:183-198. [PMID: 21162126 DOI: 10.1002/jnr.22542] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
185 Gary-Bobo G, Houssaini A, Amsellem V, Rideau D, Pacaud P, Perrin A, Brégeon J, Marcos E, Dubois-Randé JL, Sitbon O, Savale L, Adnot S. Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. Circulation 2010;122:1937-47. [PMID: 20974998 DOI: 10.1161/CIRCULATIONAHA.110.973750] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
186 Ances BM, Bhatt A, Vaida F, Rosario D, Alexander T, Marquie-Beck J, Ellis RJ, Letendre S, Grant I, McCutchan JA; HIV Neurobehavioral Research Center (HNRC) Group. Role of metabolic syndrome components in human immunodeficiency virus-associated stroke. J Neurovirol 2009;15:249-56. [PMID: 19562611 DOI: 10.1080/13550280902962443] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
187 Johns K, Saeedi R, Mancini GB, Bondy G. Ankle brachial index screening for occult vascular disease is not useful in HIV-positive patients. AIDS Res Hum Retroviruses 2010;26:955-9. [PMID: 20718628 DOI: 10.1089/aid.2009.0275] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
188 Parienti J, Verdon R. Névirapine et risque cardiovasculaire. Médecine et Maladies Infectieuses 2010;40:499-505. [DOI: 10.1016/j.medmal.2010.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
189 Anastos K, Ndamage F, Lu D, Cohen MH, Shi Q, Lazar J, Bigirimana V, Mutimura E. Lipoprotein levels and cardiovascular risk in HIV-infected and uninfected Rwandan women. AIDS Res Ther 2010;7:34. [PMID: 20796311 DOI: 10.1186/1742-6405-7-34] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
190 Guaraldi G, Zona S. From lipodystrophy to cardiovascular disease: new insight into the management of HIV infection. Clinical Lipidology 2010;5:583-593. [DOI: 10.2217/clp.10.32] [Reference Citation Analysis]
191 Mcgibbon DH. Subcutaneous Fat. Rook's Textbook of Dermatology 2010. [DOI: 10.1002/9781444317633.ch46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
192 Kohler JJ, Lewis W. Cardiovascular Toxicities of Life-Saving Drugs: Antiviral Therapy. Cardiotoxicity of Non-Cardiovascular Drugs 2010. [DOI: 10.1002/9780470660379.ch10] [Reference Citation Analysis]
193 Pinti M, Gibellini L, Guaraldi G, Orlando G, Gant TW, Morselli E, Nasi M, Salomoni P, Mussini C, Cossarizza A. Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease. AIDS 2010;24:841-50. [PMID: 20168207 DOI: 10.1097/QAD.0b013e32833779a3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
194 Shrestha S, Irvin MR, Taylor KD, Wiener HW, Pajewski NM, Haritunians T, Delaney JA, Schambelan M, Polak JF, Arnett DK, Chen YD, Grunfeld C. A genome-wide association study of carotid atherosclerosis in HIV-infected men. AIDS 2010;24:583-92. [PMID: 20009918 DOI: 10.1097/QAD.0b013e3283353c9e] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
195 Nguemaim N, Mbuagbaw J, Nkoa T, Teto G, Njitchouan G, Pouomogne D, Same-ekobo A, Asonganyi T. Changes in Lipid Profiles in Two Groups of HIV-1 Infected Patients in Cameroon on Two Treatment Regimens with Either Efavirenz or Nevirapine, in Association with Reverse Transcriptase Inhibitors. J of Medical Sciences 2010;10:25-33. [DOI: 10.3923/jms.2010.25.33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
196 Karcher C. Sculptra. Augmentation Fillers 2010. [DOI: 10.1017/cbo9780511674853.010] [Reference Citation Analysis]
197 Arimie R, Movahedi Z. Evidence-Based Decisions in Human Immunodeficiency Virus Infection and Cardiac Disease. Evidence-Based Practice: Toward Optimizing Clinical Outcomes 2010. [DOI: 10.1007/978-3-642-05025-1_6] [Reference Citation Analysis]
198 Ravussin E, Smith SR. Role of the Adipocyte in Metabolism and Endocrine Function. Endocrinology 2010. [DOI: 10.1016/b978-1-4160-5583-9.00037-x] [Reference Citation Analysis]
199 Rao MN, Mulligan K, Schambelan M. HIV Infection and Diabetes. Principles of Diabetes Mellitus 2010. [DOI: 10.1007/978-0-387-09841-8_38] [Reference Citation Analysis]
200 Pozniak A. Antiretroviral therapy for HIV. Antibiotic and Chemotherapy 2010. [DOI: 10.1016/b978-0-7020-4064-1.00043-9] [Reference Citation Analysis]
201 ANTIVIRAL DRUGS, INCLUDING IMMUNOGLOBULINS AND INTERFERONS. Meyler's Side Effects of Antimicrobial Drugs 2010. [DOI: 10.1016/b978-0-444-53272-5.50006-6] [Reference Citation Analysis]
202 Anuurad E, Semrad A, Berglund L. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord 2009;7:401-10. [PMID: 19355810 DOI: 10.1089/met.2008.0096] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis]
203 Forrester JE, Wang XD, Knox TA, Borek CG, Tang AM, Johnson EJ. Factors associated with serum retinol, alpha-tocopherol, carotenoids, and selenium in Hispanics with problems of HIV, chronic hepatitis C, and drug use. J Public Health Policy 2009;30:285-99. [PMID: 19806070 DOI: 10.1057/jphp.2009.20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
204 Ances BM, Vaida F, Rosario D, Marquie-Beck J, Ellis RJ, Simpson DM, Clifford DB, McArthur JC, Grant I, McCutchan JA; CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Metabolic Study Group. Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS 2009;23:2317-22. [PMID: 19823068 DOI: 10.1097/QAD.0b013e328332204e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
205 Karar J, Maity A. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther. 2009;8:1994-2001. [PMID: 19823031 DOI: 10.4161/cbt.8.21.9988] [Cited by in Crossref: 71] [Cited by in F6Publishing: 79] [Article Influence: 5.1] [Reference Citation Analysis]
206 Fernandez MA. Lipodistrofia relacionada con el VIH-1. Piel 2009;24:489-493. [DOI: 10.1016/s0213-9251(09)72787-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
207 Kirton CA. Tratamiento de las complicaciones a largo plazo de la infección por VIH. Nursing (Ed española) 2009;27:30-36. [DOI: 10.1016/s0212-5382(09)70619-3] [Reference Citation Analysis]
208 Raj SR, Stein CM, Saavedra PJ, Roden DM. Cardiovascular effects of noncardiovascular drugs. Circulation 2009;120:1123-32. [PMID: 19770411 DOI: 10.1161/CIRCULATIONAHA.107.728576] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
209 George JA, Venter WD, Van Deventer HE, Crowther NJ. A longitudinal study of the changes in body fat and metabolic parameters in a South African population of HIV-positive patients receiving an antiretroviral therapeutic regimen containing stavudine. AIDS Res Hum Retroviruses 2009;25:771-81. [PMID: 19619010 DOI: 10.1089/aid.2008.0308] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
210 Stöckli J, James D. GLUT4. AfCS-Nature Molecule Pages 2009. [DOI: 10.1038/mp.a001046.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
211 Hattori S, Ide K, Nakata H, Harada H, Suzu S, Ashida N, Kohgo S, Hayakawa H, Mitsuya H, Okada S. Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice. Antimicrob Agents Chemother 2009;53:3887-93. [PMID: 19546363 DOI: 10.1128/AAC.00270-09] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
212 Bashir A, Laciny E, Lassa-Claxton S, Yarasheski KE. Magnetic resonance imaging for quantifying regional adipose tissue in human immunodeficiency virus-infected persons with the cardiometabolic syndrome. J Cardiometab Syndr 2008;3:115-8. [PMID: 18453813 DOI: 10.1111/j.1559-4572.2008.07595.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
213 Calmy A, Hirschel B, Cooper DA, Carr A. A new era of antiretroviral drug toxicity. Antivir Ther 2009;14:165-79. [PMID: 19430091 DOI: 10.1177/135965350901400203] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
214 Lichtenstein KA. Antiretroviral treatment interruptions and risk of non-opportunistic diseases. Curr HIV/AIDS Rep 2009;6:77-82. [PMID: 19358778 DOI: 10.1007/s11904-009-0012-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
215 Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363. [PMID: 19361855 DOI: 10.1016/s0140-6736(09)60612-7] [Cited by in Crossref: 535] [Cited by in F6Publishing: 584] [Article Influence: 38.2] [Reference Citation Analysis]
216 Negredo E, Puig J, Aldea D, Medina M, Estany C, Pérez-Alvarez N, Rodríguez-Fumaz C, Muñoz-Moreno JA, Higueras C, Gonzalez-Mestre V, Clotet B. Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy. AIDS Res Hum Retroviruses 2009;25:451-5. [PMID: 19320569 DOI: 10.1089/aid.2008.0230] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
217 Lu G, Thomas-Geevarghese A, Anuurad E, Raghavan S, Minolfo R, Ormsby B, Karmally W, El-Sadr WM, Albu J, Berglund L. Relationship of postprandial nonesterified fatty acids, adipokines, and insulin across gender in human immunodeficiency virus-positive patients undergoing highly active antiretroviral therapy. Metab Syndr Relat Disord 2009;7:199-204. [PMID: 19320559 DOI: 10.1089/met.2008.0066] [Reference Citation Analysis]
218 Achim CL, Adame A, Dumaop W, Everall IP, Masliah E; Neurobehavioral Research Center. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol 2009;4:190-9. [PMID: 19288297 DOI: 10.1007/s11481-009-9152-8] [Cited by in Crossref: 145] [Cited by in F6Publishing: 157] [Article Influence: 10.4] [Reference Citation Analysis]
219 Woods MN, Wanke CA, Ling PR, Hendricks KM, Tang AM, Andersson CE, Dong KR, Sheehan HM, Bistrian BR. Metabolic syndrome and serum fatty acid patterns in serum phospholipids in hypertriglyceridemic persons with human immunodeficiency virus. Am J Clin Nutr 2009;89:1180-7. [PMID: 19244367 DOI: 10.3945/ajcn.2009.27444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
220 Chang CY, Whitt K, Liu Z, Caldwell SH. The Liver and Insulin Resistance: The Important Convergence of Endocrinology and Hepatology. Insulin Resistance. [DOI: 10.1007/978-1-59745-192-5_13] [Reference Citation Analysis]
221 Capeau J, Caron M, Boccara F. Pathogenesis of Antiretroviral Treatment-Associated Metabolic Syndrome. Cardiovascular Disease in AIDS 2009. [DOI: 10.1007/978-88-470-0761-1_3] [Reference Citation Analysis]
222 Boccara F, Meuleman C, Ederhy S, Lang S, Janower S, Cohen A, Raoux F. Coronary Artery Disease in HIV-Infected Patients: ClinicalPresentation,Pathophysiology, Prognosis,Prevention,and Treatment. Cardiovascular Disease in AIDS 2009. [DOI: 10.1007/978-88-470-0761-1_9] [Reference Citation Analysis]
223 Sekhar RV, Balasubramanyam A. Special Patient Populations: HIV Patients. Clinical Lipidology 2009. [DOI: 10.1016/b978-141605469-6.50047-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
224 Vigouroux C, Capeau J. Lipodystrophies et troubles métaboliques associés à l'infection par le virus de l'immunodéficience humaine (VIH) et à ses traitements. EMC - Endocrinologie - Nutrition 2009;6:1-10. [DOI: 10.1016/s1155-1941(09)51223-1] [Reference Citation Analysis]
225 Mary-krause M, Costagliola D. Coronary Heart Disease in HIV-Infected Patients: Epidemiology. Cardiovascular Disease in AIDS 2009. [DOI: 10.1007/978-88-470-0761-1_8] [Reference Citation Analysis]
226 ENDOCRINE AND METABOLIC ADVERSE EFFECTS OF NON-HORMONAL AND NON-METABOLIC DRUGS. Meyler's Side Effects of Endocrine and Metabolic Drugs 2009. [DOI: 10.1016/b978-0-444-53271-8.50011-9] [Reference Citation Analysis]
227 Stone NJ. Clinical Evaluation for Genetic and Secondary Causes of Dyslipidemia. Clinical Lipidology 2009. [DOI: 10.1016/b978-141605469-6.50016-0] [Reference Citation Analysis]
228 Spagnuolo MI, Bruzzese E, Vallone GF, Fasano N, De Marco G, Officioso A, Valerio G, Volpicelli M, Iorio R, Franzese A, Guarino A. Is resistin a link between highly active antiretroviral therapy and fat redistribution in HIV-infected children? J Endocrinol Invest 2008;31:592-6. [PMID: 18787374 DOI: 10.1007/BF03345607] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
229 Nguyen N, Holodniy M. HIV infection in the elderly. Clin Interv Aging 2008;3:453-72. [PMID: 18982916 DOI: 10.2147/cia.s2086] [Cited by in Crossref: 66] [Cited by in F6Publishing: 98] [Article Influence: 4.4] [Reference Citation Analysis]
230 Gebo KA. Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging health 2008;4:615-27. [PMID: 19915688 DOI: 10.2217/1745509X.4.6.615] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
231 Castaneda-Sceppa C, Bermudez OI, Wanke C, Forrester JE. Predictors of insulin resistance among Hispanic adults infected with or at risk of infection with the human immunodeficiency virus and hepatitis C virus. J Viral Hepat 2008;15:878-87. [PMID: 19087226 DOI: 10.1111/j.1365-2893.2008.01021.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
232 Sutinen J. The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients. PPAR Res 2009;2009:373524. [PMID: 19096512 DOI: 10.1155/2009/373524] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
233 Grima PF, Chiavaroli R, Grima P. Ultrasonographic assessment of lipodystrophy in HIV-1-infected patients. Radiol Med 2009;114:141-51. [PMID: 18956151 DOI: 10.1007/s11547-008-0333-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
234 Pluot E, Singh J, James SLJ, Davies AM, Sumathi VP, Grimer RJ. Abnormality of the infrapatellar fat pad (Hoffa's fat pad) in a patient with HIV: MR findings with histological correlation. European Journal of Radiology Extra 2008;68:29-32. [DOI: 10.1016/j.ejrex.2008.05.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
235 Glenday K, Petoumenos K, Law MG, Cooper DA. Country review: Australia. A Decade of HAART 2008. [DOI: 10.1093/acprof:oso/9780199225859.003.0006] [Reference Citation Analysis]
236 Sani MU. Myocardial disease in human immunodeficiency virus (HIV) infection: a review. Wien Klin Wochenschr 2008;120:77-87. [PMID: 18322768 DOI: 10.1007/s00508-008-0935-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
237 Benhalima K, Mathieu C, Van Wijngaerden E. Disorders of glucose metabolism in human immunodeficiency virus-infected patients. Acta Clin Belg 2008;63:227-34. [PMID: 19048699 DOI: 10.1179/acb.2008.042] [Reference Citation Analysis]
238 Huang JS, Becerra K, Fernandez S, Lee D, Mathews WC. The impact of HIV-associated lipodystrophy on healthcare utilization and costs. AIDS Res Ther 2008;5:14. [PMID: 18593479 DOI: 10.1186/1742-6405-5-14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
239 Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, Masur H, Meigs JB, Mulligan K, Reiss P, Samaras K; Working Group 1. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 2008;118:e20-8. [PMID: 18566314 DOI: 10.1161/CIRCULATIONAHA.107.189623] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.1] [Reference Citation Analysis]
240 Chantry CJ, Hughes MD, Alvero C, Cervia JS, Meyer WA 3rd, Hodge J, Borum P, Moye J Jr; PACTG 1010 Team. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics 2008;122:e129-38. [PMID: 18519448 DOI: 10.1542/peds.2007-2467] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
241 Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep 2008;10:61-70. [PMID: 18366987 DOI: 10.1007/s11883-008-0010-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
242 Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS. Review: Clinical aspects of the management of HIV lipodystrophy. Diabetes & Vascular Disease 2008;8:113-9. [DOI: 10.1177/14746514080080030201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
243 Sterling RK, Chiu S, Snider K, Nixon D. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci 2008;53:1375-82. [PMID: 17939038 DOI: 10.1007/s10620-007-9999-6] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
244 Lien LF, Lane JD. Pharmacologic Factors Affecting Glycemic Control. Type 2 Diabetes Mellitus. [DOI: 10.1007/978-1-60327-043-4_29] [Reference Citation Analysis]
245 Simha V, Garg A. Atypical Forms of Type 2 Diabetes. Type 2 Diabetes Mellitus. [DOI: 10.1007/978-1-60327-043-4_27] [Reference Citation Analysis]
246 Saumoy M, López-Dupla M, Veloso S, Alonso-Villaverde C, Domingo P, Broch M, Miranda M, Coll B, Saurí A, Vendrell J, Richart C, Vidal F. The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes. AIDS 2008;22:893-6. [PMID: 18427208 DOI: 10.1097/QAD.0b013e3282f4dde7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
247 Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D’Arminio Monforte A, Friis-Møller N. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426. [PMID: 18387667 DOI: 10.1016/s0140-6736(08)60423-7] [Cited by in Crossref: 625] [Cited by in F6Publishing: 562] [Article Influence: 41.7] [Reference Citation Analysis]
248 Melvin AJ, Kang M, Hitti J, Livingston E, Cohn SE, Stocker V, Ross AC, Watts H, Mccomsey GA. Cord Blood Lipids in Infants Born to HIV-1-Infected Women Treated with Combination Antiretroviral Therapy. Antiviral Therapy 2008;13:349-56. [DOI: 10.1177/135965350801300310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Achim C, Everall I. The Nervous System. HIV and Aging 2008. [DOI: 10.3109/9781420065985-3] [Reference Citation Analysis]
250 Pere D, Ignacio SL, Ramón T, Fernando L, Alberto T, Pompeyo V, Juan G, M José G, Paloma G, Antonio V, Jaime C, Esteban R, Bernardino R, M Luisa GA, Trinitario S, Ferran T, Juan Ramón L, Myriam G. Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort. Open AIDS J 2008;2:26-38. [PMID: 18923695 DOI: 10.2174/1874613600802010026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
251 Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M, Bryant K, Justice AC. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007;45:1593-601. [PMID: 18190322 DOI: 10.1086/523577] [Cited by in Crossref: 234] [Cited by in F6Publishing: 261] [Article Influence: 15.6] [Reference Citation Analysis]
252 Goldfine ID, Maddux BA, Youngren JF, Reaven G, Accili D, Trischitta V, Vigneri R, Frittitta L. The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocr Rev 2008;29:62-75. [PMID: 18199690 DOI: 10.1210/er.2007-0004] [Cited by in Crossref: 93] [Cited by in F6Publishing: 100] [Article Influence: 6.2] [Reference Citation Analysis]
253 Silic A, Janez A, Tomazic J, Karner P, Vidmar L, Sharma P, Maticic M. Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. Croat Med J 2007;48:791-9. [PMID: 18074413 DOI: 10.3325/cmj.2007.6.791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
254 Soriano V, Puoti M, Garcia-Gascó P, Rockstroh JK, Benhamou Y, Barreiro P, McGovern B. Antiretroviral drugs and liver injury. AIDS 2008;22:1-13. [PMID: 18090386 DOI: 10.1097/QAD.0b013e3282f0e2fd] [Cited by in Crossref: 129] [Cited by in F6Publishing: 134] [Article Influence: 8.6] [Reference Citation Analysis]
255 Mutimura E, Crowther NJ, Cade TW, Yarasheski KE, Stewart A. Exercise training reduces central adiposity and improves metabolic indices in HAART-treated HIV-positive subjects in Rwanda: a randomized controlled trial. AIDS Res Hum Retroviruses 2008;24:15-23. [PMID: 18275343 DOI: 10.1089/aid.2007.0023] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 3.8] [Reference Citation Analysis]
256 Kiesewetter DO, Knudson K, Collins M, Srinivasula S, Lim E, Di Mascio M. Enantiomeric radiochemical synthesis of R and S (1-(6-amino-9H-purin-9-yl)-3-fluoropropan-2-yloxy)methylphosphonic acid (FPMPA). J Labelled Comp Radiopharm 2008;51:187-94. [PMID: 19724660 DOI: 10.1002/jlcr.1505] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
257 Slama L, Lanoy E, Valantin M, Bastard J, Chermak A, Boutekatjirt A, William-faltaos D, Billaud E, Molina J, Capeau J, Costagliola D, Rozenbaum W. Effect of Pioglitazone on HIV-1-Related Lipodystrophy: A Randomized Double-Blind Placebo-Controlled Trial (ANRS 113). Antiviral Therapy 2008;13:67-76. [DOI: 10.1177/135965350801300107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
258 Gilmore N. Ethical issues and HAART. The HIV Pandemic 2007. [DOI: 10.1093/acprof:oso/9780199237401.003.0008] [Reference Citation Analysis]
259 Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S; INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007;21:2445-53. [PMID: 18025881 DOI: 10.1097/QAD.0b013e3282efad32] [Cited by in Crossref: 138] [Cited by in F6Publishing: 149] [Article Influence: 8.6] [Reference Citation Analysis]
260 Mccullen M, Ahmed I. Drug-Induced Hyperglycemia and Diabetes Mellitus. Type 2 Diabetes 2007. [DOI: 10.3109/9780849379581-35] [Reference Citation Analysis]
261 Mccomsey G. Mitochondrial Toxicity and Lipodystrophy. Infectious Disease. [DOI: 10.1007/978-1-59745-085-0_10] [Reference Citation Analysis]
262 Anuurad E, Thomas-Geevarghese A, Devaraj S, Albu J, Minolfo R, El-Sadr WM, Lu G, Karmally W, Berglund L. Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy. Atherosclerosis 2008;198:192-7. [PMID: 17996872 DOI: 10.1016/j.atherosclerosis.2007.09.042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
263 Simha V, Agarwal AK. Inherited and Acquired Lipodystrophies. Nutrition and Health. [DOI: 10.1007/978-1-59745-370-7_18] [Reference Citation Analysis]
264 Scevola D, Giglio O, Scevola S. Treatment of AIDS Anorexia-Cachexia Syndrome and Lipodystrophy. Cachexia and Wasting: A Modern Approach. [DOI: 10.1007/978-88-470-0552-5_41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
265 Guallar JP, Cano-soldado P, Aymerich I, Domingo JC, Alegre M, Domingo P, Villarroya F, Casado FJ, Giralt M, Pastor-anglada M. Altered Expression of Nucleoside Transporter Genes (SLC28 and SLC29) in Adipose Tissue from HIV-1–Infected Patients. Antiviral Therapy 2007;12:853-864. [DOI: 10.1177/135965350701200601] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
266 Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F; AIDS Clinical Trials Group (ACTG). Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr 2007;45:193-200. [PMID: 17527093 DOI: 10.1097/QAI.0b013e318042e204] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 2.7] [Reference Citation Analysis]
267 Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 2007;9:271-8. [PMID: 17460771 DOI: 10.1593/neo.07124] [Cited by in Crossref: 89] [Cited by in F6Publishing: 97] [Article Influence: 5.6] [Reference Citation Analysis]
268 Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther 2007;12:149-62. [PMID: 17503657 DOI: 10.1177/135965350701200214] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
269 Wood E, Montaner JS. When To Initiate HIV Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 2007;45:131-132. [DOI: 10.1097/qai.0b013e31804d684b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
270 Currier JS, Kendall MA, Henry WK, Alston-Smith B, Torriani FJ, Tebas P, Li Y, Hodis HN. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007;21:1137-45. [PMID: 17502724 DOI: 10.1097/QAD.0b013e32811ebf79] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 6.4] [Reference Citation Analysis]
271 Hulgan T. Nucleoside and nucleotide analogue reverse transcriptase inhibitor toxicity: how much longer must we wield the sword? Future HIV Therapy 2007;1:61-72. [DOI: 10.2217/17469600.1.1.61] [Reference Citation Analysis]
272 Samri A, Goodall R, Burton C, Imami N, Pantaleo G, Kelleher A, Poli G, Gotch F, Autran B. Three-Year Immune Reconstitution in PI-Sparing and PI-Containing Antiretroviral Regimens in Advanced HIV-1 Disease. Antiviral Therapy 2007;12:553-558. [DOI: 10.1177/135965350701200414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
273 Tien PC, Barrón Y, Justman JE, Hyman C, Cohen MH, Young M, Kovacs A, Cole SR. Antiretroviral therapies associated with lipoatrophy in HIV-infected women. AIDS Patient Care STDS 2007;21:297-305. [PMID: 17518522 DOI: 10.1089/apc.2006.128] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
274 Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-2512. [PMID: 17456578 DOI: 10.1210/jc.2006-2190] [Cited by in Crossref: 1106] [Cited by in F6Publishing: 1183] [Article Influence: 69.1] [Reference Citation Analysis]
275 Howard AA, Floris-Moore M, Lo Y, Arnsten JH, Fleischer N, Klein RS. Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med 2006;7:389-96. [PMID: 16903984 DOI: 10.1111/j.1468-1293.2006.00398.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
276 Igoudjil A, Abbey-toby A, Begriche K, Grodet A, Chataigner K, Peytavin G, Maachi M, Colin M, Robin M, Lettéron P, Feldmann G, Pessayre D, Fromenty B. High Doses of Stavudine Induce Fat Wasting and Mild Liver Damage without Impairing Mitochondrial Respiration in Mice. Antiviral Therapy 2007;12:389-400. [DOI: 10.1177/135965350701200314] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
277 Milinkovic A, Martinez E, López S, De Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM. The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antiviral Therapy 2007;12:407-416. [DOI: 10.1177/135965350701200301] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
278 Howard AA, Lo Y, Floris-Moore M, Klein RS, Fleischer N, Schoenbaum EE. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection. AIDS 2007;21:633-41. [PMID: 17314526 DOI: 10.1097/QAD.0b013e3280464db7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
279 Goodkin K, Symes S, Concha M, Kolber M, Asthana D, Molina R, Frasca A, Zheng W, O’mellan S, Lichtenberger M. HIV-1 infection, diabetes mellitus and psychiatric disorders. Psychiatric Disorders and Diabetes Mellitus 2007. [DOI: 10.3109/9780203931592-8] [Reference Citation Analysis]
280 Ruiz L, Paredes R, Gómez G, Romeu J, Domingo P, Pérez-Alvarez N, Tambussi G, Llibre JM, Martínez-Picado J, Vidal F, Fumaz CR, Clotet B; TIBET Study Group. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007;21:169-78. [PMID: 17197807 DOI: 10.1097/QAD.0b013e328011033a] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 4.3] [Reference Citation Analysis]
281 Karen S, Witold R, Cholewińska G. Physiotherapy of patients with lipodystrophy associated with HAART. HIV & AIDS Review 2007;6:20-22. [DOI: 10.1016/s1730-1270(10)60037-9] [Reference Citation Analysis]
282 Brett-major DM, Ganesan A. Dyslipidemia Management in Patients With Human Immunodeficiency Virus. Infectious Diseases in Clinical Practice 2007;15:7-16. [DOI: 10.1097/01.idc.0000239720.32336.99] [Reference Citation Analysis]
283 Meulenbelt J, Fijen J. Antiviral Agents. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose 2007. [DOI: 10.1016/b978-0-7216-0693-4.50058-x] [Reference Citation Analysis]
284 Ahima RS, Jackson MB. Lipodystrophy: The experiment of nature to study leptin. Leptin. [DOI: 10.1007/978-0-387-31416-7_12] [Reference Citation Analysis]
285 Lewin SR, Kaldor JM, Cooper DA. HIV research in Australia: linking basic research findings with clinical and public health outcomes. Retrovirology 2006;3:86. [PMID: 17140433 DOI: 10.1186/1742-4690-3-86] [Reference Citation Analysis]
286 Negredo E, Higueras C, Adell X, Martinez JC, Martinez E, Puig J, Fumaz CR, Muñoz-Moreno JA, Perez-Alvarez N, Videla S, Estany C, Cinquegrana D, Gonzalez-Mestre V, Clotet B. Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances. AIDS Patient Care STDS 2006;20:829-37. [PMID: 17192148 DOI: 10.1089/apc.2006.20.829] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
287 Diop ME, Bastard JP, Meunier N, Thévenet S, Maachi M, Capeau J, Pialoux G, Vigouroux C. Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients. AIDS Res Hum Retroviruses 2006;22:1242-7. [PMID: 17209766 DOI: 10.1089/aid.2006.22.1242] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
288 Calza DL, Manfredi R, Chiodo F. Cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Expert Opinion on Therapeutic Patents 2006;16:1497-516. [DOI: 10.1517/13543776.16.11.1497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
289 Prot M, Heripret L, Cardot-Leccia N, Perrin C, Aouadi M, Lavrut T, Garraffo R, Dellamonica P, Durant J, Le Marchand-Brustel Y, Binétruy B. Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice. Antimicrob Agents Chemother 2006;50:3998-4004. [PMID: 17000748 DOI: 10.1128/AAC.00625-06] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
290 Dayam R, Neamati N. HIV Therapeutics, Biochemistry of. Encyclopedia of Molecular Cell Biology and Molecular Medicine 2006. [DOI: 10.1002/3527600906.mcb.200400128] [Reference Citation Analysis]
291 Honda M, Oka S. Current therapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Int J Hematol 2006;84:18-22. [PMID: 16867897 DOI: 10.1532/IJH97.06102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
292 Asensi V, Martín-Roces E, Collazos J, Cartón JA, Maradona JA, Alonso A, Medina M, Aburto JM, Fernández C, Martínez E. Association between physical and echographic fat thickness assessments and a lipodystrophy grading scale in lipodystrophic HIV patients: practical implications. AIDS Res Hum Retroviruses 2006;22:830-6. [PMID: 16989606 DOI: 10.1089/aid.2006.22.830] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
293 Kehlenbeck S, Betz U, Birkmann A, Fast B, Göller AH, Henninger K, Lowinger T, Marrero D, Paessens A, Paulsen D, Pevzner V, Schohe-Loop R, Tsujishita H, Welker R, Kreuter J, Rübsamen-Waigmann H, Dittmer F. Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore. J Virol 2006;80:6883-94. [PMID: 16809294 DOI: 10.1128/JVI.00306-06] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
294 Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006;42:562-571. [PMID: 16837863 DOI: 10.1097/01.qai.0000229996.75116.da] [Cited by in Crossref: 100] [Cited by in F6Publishing: 116] [Article Influence: 5.9] [Reference Citation Analysis]
295 Giralt M, Domingo P, Guallar JP, de la Concepción MLR, Alegre M, Domingo JC, Villarroya F. HIV-1 Infection Alters Gene Expression in Adipose Tissue, Which Contributes to HIV-1/Haart-Associated Lipodystrophy. Antiviral Therapy 2006;11:729-740. [DOI: 10.1177/135965350601100610] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
296 Mary-Krause M, Billaud E, Poizot-Martin I, Simon A, Dhiver C, Dupont C, Salmon D, Roudiere L, Costagliola D; Clinical Epidemiology Group of the French Hospital Database. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. AIDS 2006;20:1627-35. [PMID: 16868444 DOI: 10.1097/01.aids.0000238409.90571.02] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 2.7] [Reference Citation Analysis]
297 Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 2007;166:13-21. [PMID: 16896646 DOI: 10.1007/s00431-006-0193-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 2.1] [Reference Citation Analysis]
298 de Larrañaga GF, Wingeyer SD, Puga LM, Alonso BS, Benetucci JA. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis 2006;25:98-103. [PMID: 16477441 DOI: 10.1007/s10096-006-0090-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
299 Nerurkar PV, Lee YK, Linden EH, Lim S, Pearson L, Frank J, Nerurkar VR. Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2. Br J Pharmacol 2006;148:1156-64. [PMID: 16847441 DOI: 10.1038/sj.bjp.0706821] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
300 Alfirevic A, Park B. Pharmacogenetics of Adverse Drug Reactions. Pharmacogenetics 2006. [DOI: 10.3109/9781420016697-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
301 Worrell CJ. Metabolic complications of antiretroviral therapy in children. Handbook of Pediatric HIV Care 2006. [DOI: 10.1017/cbo9780511544781.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
302 Palacios R, Merchante N, Macías J, González M, Castillo J, Ruiz J, Márquez M, Gómez-mateos J, Pineda JA, Santos J. Incidence of and Risk Factors for Insulin Resistance in Treatment-Naive HIV-Infected Patients 48 Weeks after Starting Highly Active Antiretroviral Therapy. Antiviral Therapy 2006;11:529-535. [DOI: 10.1177/135965350601100413] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
303 Collins EJ, Burgoyne RW, Wagner CA, Abbey SE, Halman MH, Nur ML, Walmsley SL. Lipodystrophy severity does not contribute to HAART nonadherence. AIDS Behav 2006;10:273-7. [PMID: 16421650 DOI: 10.1007/s10461-005-9048-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
304 Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006;20:1019-26. [PMID: 16603854 DOI: 10.1097/01.aids.0000222074.45372.00] [Cited by in Crossref: 113] [Cited by in F6Publishing: 128] [Article Influence: 6.6] [Reference Citation Analysis]
305 Gharakhanian S, Boccara F, Capeau J. Statins in HIV-associated lipodystrophy and metabolic syndrome: is there a missing link? AIDS 2006;20:1061-3. [PMID: 16603860 DOI: 10.1097/01.aids.0000222080.06293.a1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
306 Arjona MM, Pérez-Cano R, Garcia-Juárez R, Martín-Aspas A, del Alamo CF, Girón-González JA. Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: effects on leptin and TNF-alpha. AIDS Res Hum Retroviruses 2006;22:307-14. [PMID: 16623632 DOI: 10.1089/aid.2006.22.307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
307 Bard J, Lassalle R, Capeau J, Bach-ngohou K, Nazih-sanderson F, Rémy G, Reynes J, Ecobichon J, Savès M, Raffi F. Association of Apolipoproteins C3 and E with Metabolic Changes in HIV-Infected Adults Treated with a Protease-Inhibitor-Containing Antiretroviral Therapy. Antiviral Therapy 2006;11:361-370. [DOI: 10.1177/135965350601100310] [Reference Citation Analysis]
308 Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, Bienstock RJ, Ludaway T, McNaught J, Russ R, Stuart T, Santoianni R. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 2006;20:675-84. [PMID: 16514297 DOI: 10.1097/01.aids.0000216367.23325.58] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 4.7] [Reference Citation Analysis]
309 Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Wirtz V, Rightmire A, Odeshoo L, McLaren C. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-8. [PMID: 16514301 DOI: 10.1097/01.aids.0000216371.76689.63] [Cited by in Crossref: 164] [Cited by in F6Publishing: 172] [Article Influence: 9.6] [Reference Citation Analysis]
310 Tsiodras S, Mantzoros C. Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications. Am J Infect Dis 2006;2:141-52. [PMID: 17183414 DOI: 10.3844/ajidsp.2006.141.152] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 1.6] [Reference Citation Analysis]
311 Rao MN, Lee GA, Grunfeld C. Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors. Am J Infect Dis 2006;2:159-66. [PMID: 22162956 DOI: 10.3844/ajidsp.2006.159.166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
312 Hadigan C. Diabetes, insulin resistance, and HIV. Curr Infect Dis Rep 2006;8:69-75. [PMID: 16448603 DOI: 10.1007/s11908-006-0037-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
313 Law M, Puls R, Cheng AK, Cooper DA, Carr A. Evaluation of the HIV Lipodystrophy Case Definition in a Placebo-Controlled, 144-Week Study in Antiretroviral-Naive Adults. Antiviral Therapy 2006;11:179-186. [DOI: 10.1177/135965350601100205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
314 Spieker LE, Karadag B, Binggeli C, Corti R. Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection. Heart Vessels 2005;20:171-4. [PMID: 16025368 DOI: 10.1007/s00380-004-0790-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
315 Temesgen Z, Knappe-Langworthy JE, St Marie MM, Smith BA, Dierkhising RA. Comprehensive Health Enhancement Support System (CHESS) for people with HIV infection. AIDS Behav 2006;10:35-40. [PMID: 16400508 DOI: 10.1007/s10461-005-9026-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
316 Tourret J, Tostivint I, Deray G, Isnard-bagnis C. Néphropathies rencontrées au cours de l'infection par le virus de l'immunodéficience humaine (VIH). EMC - Néphrologie 2006;1:1-11. [DOI: 10.1016/s1762-0945(06)40512-x] [Reference Citation Analysis]
317 Lijnen H. Saquinavir does not affect adipose tissue development or metabolic parameters in mice on high fat diet. Thrombosis Research 2006;118:539-541. [DOI: 10.1016/j.thromres.2005.09.014] [Reference Citation Analysis]
318 Scevola D, Di Matteo A, Giglio O, Uberti F. HIV Infection-Related Cachexia and Lipodystrophy. Cachexia and Wasting: A Modern Approach 2006. [DOI: 10.1007/978-88-470-0552-5_40] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
319 Protease inhibitors. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions 2006. [DOI: 10.1016/b0-44-451005-2/00773-7] [Reference Citation Analysis]
320 Miscellaneous Infections and Atherosclerosis: Cardiovascular and Cerebrovascular Disease. Infections and the Cardiovascular System: New Perspectives. [DOI: 10.1007/0-306-47926-5_8] [Reference Citation Analysis]
321 Utech K, Berneis K. Cachexia Associated with AIDS. Pharmacotherapy of Cachexia 2005. [DOI: 10.1201/9781420048957.ch8] [Reference Citation Analysis]
322 Hamel FG, Fawcett J, Tsui BT, Bennett RG, Duckworth WC. Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells. Diabetes Obes Metab 2005;0:060721083724034. [DOI: 10.1111/j.1463-1326.2005.00542.x] [Reference Citation Analysis]
323 Burton CT, Nelson MR, Hay P, Gazzard BG, Gotch FM, Imami N. Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection. Clin Exp Immunol 2005;142:354-61. [PMID: 16232224 DOI: 10.1111/j.1365-2249.2005.02918.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
324 Mary-krause M, Costagliola D. Coronary Heart Disease in HIV-Infected Patients: Epidemiology. Cardiovascular Disease in AIDS. [DOI: 10.1007/88-470-0358-x_5] [Reference Citation Analysis]
325 Boccara F, Cohen A. Coronary Artery Disease in HIV-Infected Patients: Clinical Presentation, Pathophysiology, Prognosis, Prevention, and Treatment. Cardiovascular Disease in AIDS. [DOI: 10.1007/88-470-0358-x_6] [Reference Citation Analysis]
326 Capeau J. Pathogenesis of HAART-Associated Metabolic Syndrome. Cardiovascular Disease in AIDS. [DOI: 10.1007/88-470-0358-x_2] [Reference Citation Analysis]
327 Gebo KA, Moore RD. Managing HIV infection in middle aged and older populations. Aging Health 2005;1:395-407. [DOI: 10.2217/1745509x.1.3.395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
328 Núñez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006;44:S132-9. [PMID: 16364487 DOI: 10.1016/j.jhep.2005.11.027] [Cited by in Crossref: 166] [Cited by in F6Publishing: 169] [Article Influence: 9.2] [Reference Citation Analysis]
329 Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121-131. [PMID: 16186728 DOI: 10.1097/01.qai.0000182230.47819.aa] [Cited by in Crossref: 232] [Cited by in F6Publishing: 252] [Article Influence: 12.9] [Reference Citation Analysis]
330 Sevastianova K, Sutinen J, Westerbacka J, Ristola M, Yki-järvinen H. Arterial Stiffness in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. Antiviral Therapy 2005;10:925-935. [DOI: 10.1177/135965350501000808] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
331 Lien LF, Feinglos MN. Protease inhibitor-induced diabetic complications : incidence, management and prevention. Drug Saf 2005;28:209-26. [PMID: 15733026 DOI: 10.2165/00002018-200528030-00003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
332 Ozdener H. Molecular mechanisms of HIV-1 associated neurodegeneration. J Biosci 2005;30:391-405. [PMID: 16052077 DOI: 10.1007/BF02703676] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
333 Legrand FA, Abadi J, Jordan KA, Davenport MP, Deeks SG, Fennelly GJ, Wiznia AA, Nixon DF, Rosenberg MG. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS 2005;19:1575-85. [PMID: 16184026 DOI: 10.1097/01.aids.0000186816.99993.8e] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
334 Parruti G, Toro GM. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report. BMC Infect Dis 2005;5:80. [PMID: 16202141 DOI: 10.1186/1471-2334-5-80] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
335 Bittner B, Riek M, Holmes B, Grange S. Saquinavir 500 mg Film-Coated Tablets Demonstrate Bioequivalence to Saquinavir 200 mg Hard Capsules When Boosted with Twice-Daily Ritonavir in Healthy Volunteers. Antiviral Therapy 2005;10:803-810. [DOI: 10.1177/135965350501000703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
336 Barrios A, Negredo E, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Santos J, Clotet B, Soriano V, for the EFADITE Study Group. Simplification Therapy with Once-Daily Didanosine, Tenofovir and Efavirenz in HIV-1-Infected Adults with Viral Suppression Receiving a More Complex Antiretroviral Regimen: Final Results of the EFADITE Trial. Antiviral Therapy 2005;10:825-832. [DOI: 10.1177/135965350501000708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
337 Sax PE, Gathe JC Jr. Beyond efficacy: the impact of combination antiretroviral therapy on quality of life. AIDS Patient Care STDS 2005;19:563-76. [PMID: 16164383 DOI: 10.1089/apc.2005.19.563] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
338 Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ; ACTG 5087 Study Team. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005;21:757-67. [PMID: 16218799 DOI: 10.1089/aid.2005.21.757] [Cited by in Crossref: 88] [Cited by in F6Publishing: 95] [Article Influence: 4.9] [Reference Citation Analysis]
339 Hadigan C, Kamin D, Liebau J, Mazza S, Barrow S, Torriani M, Rubin R, Weise S, Fischman A, Grinspoon S. Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. Am J Physiol Endocrinol Metab 2006;290:E289-98. [PMID: 16131513 DOI: 10.1152/ajpendo.00273.2005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
340 Burgoyne R, Collins E, Wagner C, Abbey S, Halman M, Nur M, Walmsley S. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res 2005;14:981-90. [PMID: 16041895 DOI: 10.1007/s11136-004-2580-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
341 Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. J Virol 2005;79:2087-96. [PMID: 15681411 DOI: 10.1128/JVI.79.4.2087-2096.2005] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
342 Jacobs B, Neil N, Aboulafia DM. Retrospective analysis of suspending HAART in selected patients with controlled HIV replication. AIDS Patient Care STDS 2005;19:429-38. [PMID: 16053400 DOI: 10.1089/apc.2005.19.429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
343 Umpleby AM, Das S, Stolinski M, Shojaee-moradie F, Jackson NC, Jefferson W, Crabtree N, Nightingale P, Shahmanesh M. Low Density Lipoprotein Apolipoprotein B Metabolism in Treatment-Naive HIV Patients and Patients on Antiretroviral Therapy. Antiviral Therapy 2005;10:663-670. [DOI: 10.1177/135965350501000508] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
344 Chaparro J, Reeds DN, Wen W, Xueping E, Klein S, Semenkovich CF, Bae KT, Quirk EK, Powderly WG, Yarasheski KE, Li E. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. Metabolism 2005;54:561-7. [PMID: 15877283 DOI: 10.1016/j.metabol.2004.08.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
345 Albuquerque EM, de Faria EC, Oliveira HC, Magro DO, Castilho LN. High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus. BMC Infect Dis 2005;5:47. [PMID: 15955243 DOI: 10.1186/1471-2334-5-47] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
346 Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, Schouten J, Mickelberg K, Li Y, Hodis HN; AACTG 5078 Study Team. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005;19:927-33. [PMID: 15905673 DOI: 10.1097/01.aids.0000171406.53737.f9] [Cited by in Crossref: 128] [Cited by in F6Publishing: 134] [Article Influence: 7.1] [Reference Citation Analysis]
347 Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA, Williams CM, Phair JP; Multicenter AIDS Cohort Study. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005;19:953-60. [PMID: 15905677 DOI: 10.1097/01.aids.0000171410.76607.f8] [Cited by in Crossref: 224] [Cited by in F6Publishing: 242] [Article Influence: 12.4] [Reference Citation Analysis]
348 Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, Schneider ME, de Wolf F, Boer K, van der Ende ME; Dutch HMF Study Group. Nelfinavir and nevirapine side effects during pregnancy. AIDS 2005;19:795-9. [PMID: 15867493 DOI: 10.1097/01.aids.0000168973.59466.14] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 2.8] [Reference Citation Analysis]
349 Kamin DS, Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS 2005;19:641-52. [PMID: 15821390 DOI: 10.1097/01.aids.0000166087.08822.bc] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 3.3] [Reference Citation Analysis]
350 Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-94. [PMID: 15821394 DOI: 10.1097/01.aids.0000166091.39317.99] [Cited by in Crossref: 174] [Cited by in F6Publishing: 158] [Article Influence: 9.7] [Reference Citation Analysis]
351 Worrell CJ. Metabolic complications of antiretroviral therapy in children. Textbook of Pediatric HIV Care 2005. [DOI: 10.1017/cbo9780511544798.023] [Reference Citation Analysis]
352 Howard AA, Floris-Moore M, Arnsten JH, Santoro N, Fleischer N, Lo Y, Schoenbaum EE. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 2005;40:1492-9. [PMID: 15844072 DOI: 10.1086/429824] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 2.8] [Reference Citation Analysis]
353 Nolan D, Reiss P, Mallal S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf 2005;4:201-18. [PMID: 15794714 DOI: 10.1517/14740338.4.2.201] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
354 Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005;19:585-92. [PMID: 15802977 DOI: 10.1097/01.aids.0000163935.99401.25] [Cited by in Crossref: 137] [Cited by in F6Publishing: 142] [Article Influence: 7.6] [Reference Citation Analysis]
355 Adler-Wailes DC, Liu H, Ahmad F, Feng N, Londos C, Manganiello V, Yanovski JA. Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis. J Clin Endocrinol Metab 2005;90:3251-61. [PMID: 15741249 DOI: 10.1210/jc.2004-2194] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
356 Valcour VG, Shikuma CM, Shiramizu BT, Williams AE, Watters MR, Poff PW, Grove JS, Selnes OA, Sacktor NC. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;38:31-6. [PMID: 15608521 DOI: 10.1097/00126334-200501010-00006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 84] [Article Influence: 4.2] [Reference Citation Analysis]
357 Levy AR, McCandless L, Harrigan PR, Hogg RS, Bondy G, Iloeje UH, Mukherjee J, Montaner JS. Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis 2005;4:4. [PMID: 15705191 DOI: 10.1186/1476-511X-4-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
358 Galluzzi L, Pinti M, Guaraldi G, Mussini C, Troiano L, Roat E, Giovenzana C, Nemes E, Nasi M, Orlando G, Salomoni P, Cossarizza A. Altered Mitochondrial Rna Production in Adipocytes from HIV-Infected Individuals with Lipodystrophy. Antiviral Therapy 2005;10:91-99. [DOI: 10.1177/135965350501002s10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
359 Sánchez Torres AM, Munoz Muniz R, Madero R, Borque C, García-Miguel MJ, De José Gómez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005;164:271-6. [PMID: 15650834 DOI: 10.1007/s00431-004-1610-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
360 Smit E, Semba RD, Pilibosian E, Vlahov D, Tun W, Purvis L, Tang AM. Body habitus in a cohort of HIV-seropositive and HIV-seronegative injection drug users. AIDS Patient Care STDS 2005;19:19-30. [PMID: 15665632 DOI: 10.1089/apc.2005.19.19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
361 the Swiss HIV Cohort Study, Young J, Rickenbach M, Weber R, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC, Battegay M, Bernasconi E, Böni J, Bucher H, Bürgisser P, Cattacin S, Dubs R, Egger M, Elzi L, Erb P, Fantelli K, Fischer M, Flepp M, Fontana A, Furrer H, Gorgievski M, Günthard H, Hirschel B, Kaiser L, Kind C, Klimkait T, Ledergerber B, Lauper U, Opravil M, Paccaud F, Pantaleo G, Perrin L, Piffaretti J, Rickenbach M, Rudin C, Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S. Body Fat Changes among Antiretroviral-Naive Patients on Pi- and Nnrti-Based Haart in the Swiss HIV Cohort Study. Antiviral Therapy 2005;10:73-81. [DOI: 10.1177/135965350501000105] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
362 Mir Meda J, Zamora Tall L, Tuset Creus M, Sued O, Lpez Su E, Blanco Arvalo J, Garca Alcaide F, Martnez Chamorro E, Mallolas Masferrer J, Gatell Artigas J. Infecci?n por el VIH: tratamiento antirretrov?rico de la infecci?n por el VIH en adultos. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2004;9:1461-1480. [DOI: 10.1016/s0211-3449(04)70225-8] [Reference Citation Analysis]
363 Moltó J, Ruiz L, Romeu J, Martínez-Picado J, Negredo E, Tural C, Sirera G, Clotet B. Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. AIDS Res Hum Retroviruses 2004;20:1283-8. [PMID: 15650419 DOI: 10.1089/aid.2004.20.1283] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
364 Caron M, Auclair M, Lagathu C, Lombès A, Walker UA, Kornprobst M, Capeau J. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004;18:2127-36. [PMID: 15577645 DOI: 10.1097/00002030-200411050-00004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 4.2] [Reference Citation Analysis]
365 van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004;1:e19. [PMID: 15526045 DOI: 10.1371/journal.pmed.0010019] [Cited by in Crossref: 177] [Cited by in F6Publishing: 190] [Article Influence: 9.3] [Reference Citation Analysis]
366 Maisonneuve C, Igoudjil A, Begriche K, Lettéron P, Guimont MC, Bastin J, Laigneau JP, Pessayre D, Fromenty B. Effects of zidovudine, stavudine and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting. Antivir Ther 2004;9:801-10. [PMID: 15535418 DOI: 10.1177/135965350400900513] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
367 Yerly S, Günthard HF, Fagard C, Joos B, Perneger TV, Hirschel B, Perrin L; Swiss HIV Cohort Study. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 2004;18:1951-3. [PMID: 15353981 DOI: 10.1097/00002030-200409240-00011] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 3.5] [Reference Citation Analysis]
368 McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. AIDS 2004;18:1753-68. [PMID: 15316336 DOI: 10.1097/00002030-200409030-00004] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 3.4] [Reference Citation Analysis]
369 Ferrer E, Santamariña E, Domingo P, Fumero E, Ribera E, Knobel H, Lopez JC, Barrios A, Podzamczer D. Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less. AIDS 2004;18:1727-9. [PMID: 15280785 DOI: 10.1097/01.aids.0000131381.07609.19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
370 Smith CJ, Sabin CA. The Problems Faced When Assessing the Prevalence and Incidence of Antiretroviral-Related Toxicities. Antiviral Therapy 2004;9:865-878. [DOI: 10.1177/135965350400900614] [Reference Citation Analysis]
371 Maher B, Lloyd J, Wilkins EG, Fraser WD, Back D, Park BK, Pirmohamed M. Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf-α and Tnf-Receptor Levels, and on Metabolic Parameters. Antiviral Therapy 2004;9:879-887. [DOI: 10.1177/135965350400900601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
372 European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004;18:1443-51. [PMID: 15199321 DOI: 10.1097/01.aids.0000131334.38172.01] [Cited by in Crossref: 126] [Cited by in F6Publishing: 132] [Article Influence: 6.6] [Reference Citation Analysis]
373 Martínez E, Tuset M, Milinkovic A, Miró JM, Gatell JM. Management of Dyslipidaemia in HIV-Infected Patients Receiving Antiretroviral Therapy. Antiviral Therapy 2004;9:649-663. [DOI: 10.1177/135965350400900507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
374 Yang Y, Zhu WJ, Paton NI. Comparison of Dual-Energy X-Ray Absorptiometry Machines for Measuring Fat Distribution Changes of HIV-Associated Lipodystrophy. Antiviral Therapy 2004;9:771-778. [DOI: 10.1177/135965350400900516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
375 Maggi P, Lillo A, Perilli F, Maserati R, Chirianni A; PREVALEAT Group. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 2004;18:1023-8. [PMID: 15096805 DOI: 10.1097/00002030-200404300-00010] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 3.5] [Reference Citation Analysis]
376 Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N, Freund J, Cooper DA; Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004;18:1029-36. [PMID: 15096806 DOI: 10.1097/00002030-200404300-00011] [Cited by in Crossref: 224] [Cited by in F6Publishing: 232] [Article Influence: 11.8] [Reference Citation Analysis]
377 Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003;63:2555-74. [PMID: 14636077 DOI: 10.2165/00003495-200363230-00001] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 3.5] [Reference Citation Analysis]
378 Negredo E, Ribalta J, Ferré R, Salazar J, Rey-Joly C, Sirera G, Masana L, Clotet B. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 2004;18:819-21. [PMID: 15075521 DOI: 10.1097/00002030-200403260-00017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
379 Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen BK. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 2004;135:273-9. [PMID: 14738456 DOI: 10.1111/j.1365-2249.2004.02367.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
380 Driscoll SD, Meininger GE, Lareau MT, Dolan SE, Killilea KM, Hadigan CM, Lloyd-Jones DM, Klibanski A, Frontera WR, Grinspoon SK. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004;18:465-73. [PMID: 15090799 DOI: 10.1097/00002030-200402200-00013] [Cited by in Crossref: 88] [Cited by in F6Publishing: 89] [Article Influence: 4.6] [Reference Citation Analysis]
381 the Study Swiss HIV Cohort, Kaufmann GR, Khanna N, Weber R, Perrin L, Furrer H, Cavassini M, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Bachmann S, Battegay M, Bernasconi E, Bucher H, Burgisser P, Cattacin S, Egger M, Erb P, Fierz W, Fischer M, Flepp M, Fontana A, Francioli P, Furrer H, Gorgievski M, Gunthard H, Hirschel B, Kaiser L, Kind C, Klimkait T, Ledergerber B, Lauper U, Opravil M, Paccaud F, Pantaleo G, Perrin L, Piffaretti C, Rickenbach M, Rudin C, Schupbach J, Speck R, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S. Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. Antiviral Therapy 2004;9:263-274. [DOI: 10.1177/135965350400900212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
382 Gougeon M, Pénicaud L, Fromenty B, Leclercq P, Viard J, Capeau J. Adipocytes Targets and Actors in the Pathogenesis of HIV-Associated Lipodystrophy and Metabolic Alterations. Antiviral Therapy 2004;9:161-177. [DOI: 10.1177/135965350400900206] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
383 Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Møller A, Sørensen HT, Obel N. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 2004;18:89-97. [PMID: 15090834 DOI: 10.1097/00002030-200401020-00011] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 3.9] [Reference Citation Analysis]
384 Foli A, Maserati R, Barasolo G, Castelli F, Tomasoni L, Migliorino M, Maggiolo F, Pan A, Paolucci S, Scudeller L, Tinelli C, D'aquila R, Lisziewicz J, Lori F. Strategies to Decrease Viral Load Rebound, and Prevent Loss of Cd4 and Onset of Resistance during Structured Treatment Interruptions. Antiviral Therapy 2004;9:123-32. [DOI: 10.1177/135965350400900114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
385 Varriale P, Saravi G, Hernandez E, Carbon F. Acute myocardial infarction in patients infected with human immunodeficiency virus. Am Heart J 2004;147:55-9. [PMID: 14691419 DOI: 10.1016/j.ahj.2003.07.007] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 2.4] [Reference Citation Analysis]
386 Tungsiripat-gerber M, Aberg JA. Gender-Specific Issues in the Metabolic Complications of HIV Disease and Its Treatment. Principles of Gender-Specific Medicine 2004. [DOI: 10.1016/b978-012440905-7/50359-5] [Reference Citation Analysis]
387 Antonioiribarren J, Labarga P, Rubio R, Berenguer J, Miró J, Antela A, González J, Moreno S, Arrizabalaga J, Chamorro L, Clotet B, Gatell JM, López-aldeguer J, Martínez E, Polo R, Tuset M, Viciana P, Miguel Santamaría J, María Kindelán J, Ribera E, Segura F. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004). Enfermedades Infecciosas y Microbiología Clínica 2004;22:564-642. [DOI: 10.1016/s0213-005x(04)73163-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
388 Horowitz HW, Wormser GP. Care of the Adult Patient with HIV Infection. AIDS and Other Manifestations of HIV Infection 2004. [DOI: 10.1016/b978-012764051-8/50015-9] [Reference Citation Analysis]
389 Theme 6 Genotypic resistance tests for the management of patients at simplification of highly active antiretroviral therapy. Scandinavian Journal of Infectious Diseases 2003;35:82-85. [DOI: 10.1080/03008870310009795] [Reference Citation Analysis]
390 Goetzman ES, Tian L, Nagy TR, Gower BA, Schoeb TR, Elgavish A, Acosta EP, Saag MS, Wood PA. HIV protease inhibitor ritonavir induces lipoatrophy in male mice. AIDS Res Hum Retroviruses 2003;19:1141-50. [PMID: 14709251 DOI: 10.1089/088922203771881248] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
391 Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-86. [PMID: 14600519 DOI: 10.1097/00002030-200311210-00010] [Cited by in Crossref: 394] [Cited by in F6Publishing: 419] [Article Influence: 19.7] [Reference Citation Analysis]
392 Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003;17:2345-9. [PMID: 14571186 DOI: 10.1097/00002030-200311070-00009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 2.0] [Reference Citation Analysis]
393 van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F; ATHENA Cohort Study Group. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003;17:2227-36. [PMID: 14523280 DOI: 10.1097/00002030-200310170-00011] [Cited by in Crossref: 127] [Cited by in F6Publishing: 130] [Article Influence: 6.4] [Reference Citation Analysis]
394 Lisziewicz J, Foli A, Wainberg M, Lori F. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns. Drug Saf 2003;26:605-24. [PMID: 12814330 DOI: 10.2165/00002018-200326090-00002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
395 Brambilla AM, Novati R, Calori G, Meneghini E, Vacchini D, Luzi L, Castagna A, Lazzarin A. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS 2003;17:1993-5. [PMID: 12960836 DOI: 10.1097/00002030-200309050-00022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 1.9] [Reference Citation Analysis]
396 Visnegarwala F, Darcourt J, Sajja P, Menon V, Ong O, Maldonado M, White, AC. Changes in Metabolic Profile Among Antiretroviral-Naive Patients Initiating Protease Inhibitor Versus Non–Protease Inhibitor Containing HAART Regimens. JAIDS Journal of Acquired Immune Deficiency Syndromes 2003;33:653-655. [DOI: 10.1097/00126334-200308150-00018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
397 Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63:769-802. [PMID: 12662125 DOI: 10.2165/00003495-200363080-00004] [Cited by in Crossref: 290] [Cited by in F6Publishing: 305] [Article Influence: 14.5] [Reference Citation Analysis]
398 Vigouroux C, Maachi M, Nguyên TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, Bastard JP. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003;17:1503-11. [PMID: 12824788 DOI: 10.1097/00002030-200307040-00011] [Cited by in Crossref: 153] [Cited by in F6Publishing: 163] [Article Influence: 7.7] [Reference Citation Analysis]
399 Ioannidis JP, Trikalinos TA, Law M, Carr A, Carr A, Barr D, Cooper D, Emery S, Grinspoon S, Ioannidis J, Lewis R, Law M, Lichtenstein K, Murray J, Pizzuti D, Powderly W, Rozenbaum W, Schambelan M, Puls R, Emery S, Moore A, Miller J, Carr A, Belloso W, Ivalo S, Clara L, Barcan L, Stern L, Galich A, Perman M, Losso M, Duran A, Toibaro J, Baker D, Vale R, Mcfarlane R, Macleod H, Kidd J, Genn B, Carr A, Fielden R, Mallal S, French M, Cain A, Skett J, Maxwell D, Mijch A, Hoy J, Pierce A, Mccormick C, De Graaf B, Falutz J, Vatistas J, Dion L, Montaner J, Harris M, Phillips P, Montessori V, Valyi M, Stewart W, Walmsley S, Casciaro L, Lundgren J, Andersen O, Gronholdt A, Beguinot I, Mercié P, Chêne G, Reynes J, Cotte L, Rozenbaum W, Nait-ighil L, Slama L, Nguyen T, Rousselle C, Viard J, Roudière L, Maignan A, Burgard M, Mauss S, Schmutz G, Scholten S, Oka S, Fraser H, Ishihara M, Itoh K, Reiss P, van der Valk M, Leunissen P, Nievaard M, van Ecksmit B, Kujik CC, Paton N, Peperstraete B, Karim F, Khim CY, Ong S, Gatell J, Martinez E, Milinkovic A, Churchill D, Timaeus C, Maher T, Perry N, Bray A, Moyle G, Baldwin C, Higgs C, Reynolds B, Carpenter C, Bausserman L, Fiore T, Dispigno M, Cohen C, Hellinger J, Foy K, Hubka S, Riccio B, El-sadr W, Raghavan S, Chowdury N, de Vries B, Miller S, Hammer S, Crawford M, Chang S, Dobkin J, Quagliarello B, Gallagher D, Punyanitya M, Kessler H, Tenorio A, Kjos S, Falloon J, Lane H, Rock D, Ehler L, Lichtenstein K, Mcclain T, Murphy R, Milne P, Powderly W, Aberg J, Klebert M, Conklin M, Ward D, Green L, Stearn B, the HIV Lipodystrophy Case Definition Study Group, Coordinating committee, Investigators. HIV Lipodystrophy Case Definition using Artificial Neural Network Modelling. Antiviral Therapy 2003;8:435-441. [DOI: 10.1177/135965350300800511] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
400 Yerly S, Fagard C, Günthard HF, Hirschel B, Perrin L; the Swiss HIV Cohort Study (SHCS). Drug Resistance Mutations during Structured Treatment Interruptions. Antiviral Therapy 2003;8:411-5. [DOI: 10.1177/135965350300800508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
401 Lundgren JD. Dyslipidaemia and cardiovascular disease risk associated with antiretroviral drugs. Pharmacoepidem Drug Safe 2003;12:357-359. [DOI: 10.1002/pds.807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
402 Garg A, Misra A. Lipodystrophies and Diabetes. International Textbook of Diabetes Mellitus 2003. [DOI: 10.1002/0470862092.d0509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
403 Bitnun A, Sochett E, Babyn P, Holowka S, Stephens D, Read S, King SM. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS 2003;17:1319-27. [PMID: 12799553 DOI: 10.1097/00002030-200306130-00006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 1.9] [Reference Citation Analysis]
404 Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect 2003;79:137-41. [PMID: 12690137 DOI: 10.1136/sti.79.2.137] [Cited by in Crossref: 106] [Cited by in F6Publishing: 113] [Article Influence: 5.3] [Reference Citation Analysis]
405 . European guidelines for the clinical management and treatment of HIV-infected adults in Europe: . AIDS 2003;17:S3-S26. [DOI: 10.1097/00002030-200306002-00002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
406 Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002;41:1195-1211. [PMID: 12405866 DOI: 10.2165/00003088-200241140-00004] [Cited by in Crossref: 127] [Cited by in F6Publishing: 129] [Article Influence: 6.4] [Reference Citation Analysis]
407 Escaut L, Monsuez JJ, Chironi G, Merad M, Teicher E, Smadja D, Simon A, Vittecoq D. Coronary artery disease in HIV infected patients. Intensive Care Med 2003;29:969-73. [PMID: 12739013 DOI: 10.1007/s00134-003-1740-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 2.3] [Reference Citation Analysis]
408 Jan V, Cervera P, Maachi M, Baudrimont M, Kim M, Vidal H, Girard P, Levan P, Rozenbaum W, Lombès A, Capeau J, Bastard J. Altered Fat Differentiation and Adipocytokine Expression are Inter-Related and Linked to Morphological Changes and Insulin Resistance in HIV-1-Infected Lipodystrophic Patients. Antiviral Therapy 2004;9:555-64. [DOI: 10.1177/135965350400900412] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
409 Friis-møller N, Weber R, Reiss P, Thiébaut R, Kirk O, Monforte AD, Pradier C, Morfeldt L, Mateu S, Law M, El-sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study: . AIDS 2003;17:1179-93. [DOI: 10.1097/00002030-200305230-00010] [Cited by in Crossref: 699] [Cited by in F6Publishing: 701] [Article Influence: 35.0] [Reference Citation Analysis]
410 Lai S, Lai H, Celentano DD, Vlahov D, Ren S, Margolick J, Lima JA, Bartlett JG. Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors. AIDS Patient Care STDS 2003;17:211-9. [PMID: 12816615 DOI: 10.1089/108729103321655863] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
411 Tréluyer JM, Morini JP, Dimet J, Gorin I, Rey E, Deleuze J, Ceccaldi PF, Escande JP, Pons G, Dupin N. High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2002;46:4009-12. [PMID: 12435713 DOI: 10.1128/AAC.46.12.4009-4012.2002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
412 Rudich A, Konrad D, Török D, Ben-Romano R, Huang C, Niu W, Garg RR, Wijesekara N, Germinario RJ, Bilan PJ, Klip A. Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues. Diabetologia 2003;46:649-58. [PMID: 12712244 DOI: 10.1007/s00125-003-1080-1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 4.7] [Reference Citation Analysis]
413 Dinsmoor MJ, Forrest ST. Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy. Infect Dis Obstet Gynecol 2002;10:187-91. [PMID: 12648312 DOI: 10.1155/S1064744902000212] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
414 Mauss S, Berger F, Carls H, Schmutz G. Rapid development of central adiposity after postexposure prophylaxis with antiretroviral drugs: a proof of principle? AIDS 2003;17:944-5. [PMID: 12660554 DOI: 10.1097/00002030-200304110-00032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
415 Palacios R, Santos J, Ruiz J, González M, Márquez M. Factors associated with the development of diabetes mellitus in HIV-infected patients on antiretroviral therapy: a case-control study. AIDS 2003;17:933-5. [PMID: 12660547 DOI: 10.1097/00002030-200304110-00025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
416 Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003;17:851-9. [PMID: 12660532 DOI: 10.1097/00002030-200304110-00010] [Cited by in Crossref: 78] [Cited by in F6Publishing: 84] [Article Influence: 3.9] [Reference Citation Analysis]
417 Collazos J, Mayo J, Ibarra S, Cazallas J. Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection. AIDS 2003;17:927-9. [DOI: 10.1097/00002030-200304110-00023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
418 Fantoni M, Del Borgo C, Autore C. Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2003;17 Suppl 1:S162-9. [PMID: 12870543 DOI: 10.1097/00002030-200304001-00020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
419 Domingo P, Sambeat MA, Pérez A, Ordoñez J, Rodríguez J, Vázquez G. Fat Distribution and Metabolic Abnormalities in HIV-Infected Patients on First Combination Antiretroviral Therapy Including Stavudine or Zidovudine: Role of Physical Activity as a Protective Factor. Antiviral Therapy 2003;8:223-231. [DOI: 10.1177/135965350300800306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
420 Behrens GM, Meyer-Olson D, Stoll M, Schmidt RE. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003;17 Suppl 1:S149-54. [PMID: 12870541 DOI: 10.1097/00002030-200304001-00018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.4] [Reference Citation Analysis]
421 Vittecoq D, Escaut L, Chironi G, Teicher E, Monsuez JJ, Andrejak M, Simon A. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 2003;17 Suppl 1:S70-6. [PMID: 12870533 DOI: 10.1097/00002030-200304001-00010] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 3.0] [Reference Citation Analysis]
422 Calmy A, Hirschel B, Hans D, Karsegard VL, Meier CA. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS 2003;17:770-2. [PMID: 12646807 DOI: 10.1097/00002030-200303280-00022] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 1.8] [Reference Citation Analysis]
423 Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003;17:513-20. [PMID: 12598771 DOI: 10.1097/00002030-200303070-00006] [Cited by in Crossref: 158] [Cited by in F6Publishing: 171] [Article Influence: 7.9] [Reference Citation Analysis]
424 Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C, Oksenhendler E, Weiss L, Gastaut JA, Goujard C, Rouzioux C, Maral J, Delfraissy JF, Emilie D, Aboulker JP; ANRS 079 Study Group. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003;17:343-51. [PMID: 12556688 DOI: 10.1097/00002030-200302140-00008] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 4.3] [Reference Citation Analysis]
425 van der Valk M, Sauerwein HP, Kastelein JJ, Reiss P. Lipodystrophy associated with treatment of HIV-1 infection. Adverse Drug Reaction Bulletin 2003;&NA;:835-838. [DOI: 10.1097/00012995-200302000-00001] [Reference Citation Analysis]
426 Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO. Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS 2003;17:189-94. [PMID: 12545078 DOI: 10.1097/00002030-200301240-00008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
427 García F, Plana M, Arnedo M, Ortiz GM, Miró JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS 2003;17:43-51. [PMID: 12478068 DOI: 10.1097/00002030-200301030-00007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 1.8] [Reference Citation Analysis]
428 Ben-Romano R, Rudich A, Török D, Vanounou S, Riesenberg K, Schlaeffer F, Klip A, Bashan N. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 2003;17:23-32. [PMID: 12478066 DOI: 10.1097/00002030-200301030-00005] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 3.2] [Reference Citation Analysis]
429 Green ML. Evaluation and management of dyslipidemia in patients with HIV infection. J Gen Intern Med 2002;17:797-810. [PMID: 12390557 DOI: 10.1046/j.1525-1497.2002.20201.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 2.0] [Reference Citation Analysis]
430 Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, Mussini C, Sollima S, Melzi S, Bongiovanni M, Tordato F, Cicconi P, Castelnuovo B, Rusconi S, Monforte AD. Simplification of Protease Inhibitor-Containing Regimens with Efavirenz, Nevirapine or Abacavir: Safety and Efficacy Outcomes. Antiviral Therapy 2003;8:27-35. [DOI: 10.1177/135965350300800104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
431 Woods MN, Hendricks KM. Treatment of Hyperlipidemia and Insulin Resistance with Diet. Lipodystrophy Syndrome in HIV 2003. [DOI: 10.1007/978-1-4615-0471-9_9] [Reference Citation Analysis]
432 Shevitz AH. Epidemiology of Fat Redistribution in HIV. Lipodystrophy Syndrome in HIV 2003. [DOI: 10.1007/978-1-4615-0471-9_2] [Reference Citation Analysis]
433 Schwenk A. Ernährungsmedizinische Aspekte chronischer Infektionskrankheiteil, Mangelernährung und Wasting. Praxishandbuch klinische Ernährung und Infusionstherapie 2003. [DOI: 10.1007/978-3-642-55896-2_58] [Reference Citation Analysis]
434 Husak R, Orfanos CE. HIV infection and AIDS: present status of antiretroviral therapy. European Handbook of Dermatological Treatments 2003. [DOI: 10.1007/978-3-662-07131-1_41] [Reference Citation Analysis]
435 Khatami H, Mulligan K. Body Composition in HIV Lipodystrophy. Lipodystrophy Syndrome in HIV 2003. [DOI: 10.1007/978-1-4615-0471-9_3] [Reference Citation Analysis]
436 Belda Mira A, Albert Contell A, Gómez Belda A, García Ferrer L. Síndrome de lipodistrofia asociado a la infección por el virus de la inmunodeficiencia humana y lipomatosis mediastínica. Revista Clínica Española 2003;203:99-100. [DOI: 10.1016/s0014-2565(03)71214-4] [Reference Citation Analysis]
437 Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, Yeni P. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002;16:2447-54. [PMID: 12461419 DOI: 10.1097/00002030-200212060-00010] [Cited by in Crossref: 142] [Cited by in F6Publishing: 148] [Article Influence: 6.8] [Reference Citation Analysis]
438 Behrens GM, Boerner AR, Weber K, van den Hoff J, Ockenga J, Brabant G, Schmidt RE. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 2002;110:1319-27. [PMID: 12417571 DOI: 10.1172/JCI15626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 16] [Article Influence: 0.0] [Reference Citation Analysis]
439 Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002;16:2183-93. [PMID: 12409740 DOI: 10.1097/00002030-200211080-00011] [Cited by in Crossref: 136] [Cited by in F6Publishing: 138] [Article Influence: 6.5] [Reference Citation Analysis]
440 Miller J, Brown D, Amin J, Kent-Hughes J, Law M, Kaldor J, Cooper DA, Carr A. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 2002;16:2195-200. [PMID: 12409741 DOI: 10.1097/00002030-200211080-00012] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 3.1] [Reference Citation Analysis]
441 James J, Carruthers A, Carruthers J. HIV-Associated Facial Lipoatrophy. Dermatologic Surgery 2002;28:979-986. [DOI: 10.1097/00042728-200211000-00002] [Reference Citation Analysis]
442 Barrios A, Blanco F, García-Benayas T, Gómez-Viera JM, de la Cruz JJ, Soriano V, González-Lahoz J. Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 2002;16:2079-81. [PMID: 12370508 DOI: 10.1097/00002030-200210180-00014] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 1.9] [Reference Citation Analysis]
443 Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002;16:2013-8. [PMID: 12370499 DOI: 10.1097/00002030-200210180-00005] [Cited by in Crossref: 79] [Cited by in F6Publishing: 86] [Article Influence: 3.8] [Reference Citation Analysis]
444 Haque M, Sanyal AJ. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2002;16:709-31. [PMID: 12406441 DOI: 10.1053/bega.2002.0325] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 4.6] [Reference Citation Analysis]
445 Levan P, Nguyen TH, Lallemand F, Mazetier L, Mimoun M, Rozenbaum W, Girard PM. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS 2002;16:1985-7. [PMID: 12351969 DOI: 10.1097/00002030-200209270-00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
446 Costa A, Pulido F, Rubio R, Cepeda C, Torralba M, Costa JR. Lipid changes in HIV-infected patients who started rescue therapy with an amprenavir/ritonavir-based highly active antiretroviral therapy. AIDS 2002;16:1983-4. [PMID: 12351968 DOI: 10.1097/00002030-200209270-00025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
447 Oette M, Juretzko P, Kroidl A, Sagir A, Wettstein M, Siegrist J, Häussinger D. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care STDS 2002;16:413-7. [PMID: 12396693 DOI: 10.1089/108729102760330254] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 2.4] [Reference Citation Analysis]
448 Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, Francioli P, D'Arminio Monforte A, Fox Z, Lundgren JD; EuroSIDA study group. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002;16:1663-71. [PMID: 12172088 DOI: 10.1097/00002030-200208160-00012] [Cited by in Crossref: 207] [Cited by in F6Publishing: 224] [Article Influence: 9.9] [Reference Citation Analysis]
449 Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS 2002;16:1587-94. [PMID: 12172079 DOI: 10.1097/00002030-200208160-00003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 1.7] [Reference Citation Analysis]
450 Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM, Hirsch MS. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002;46:1336-9. [PMID: 11959565 DOI: 10.1128/AAC.46.5.1336-1339.2002] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 3.3] [Reference Citation Analysis]
451 Nolan D, Hammond E, James I, Mckinnon E, Mallal S. Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level. Antiviral Therapy 2003;8:617-26. [DOI: 10.1177/135965350300800614] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
452 Wanke C, Polsky B, Kotler D. Guidelines for using body composition measurement in patients with human immunodeficiency virus infection. AIDS Patient Care STDS 2002;16:375-88. [PMID: 12227988 DOI: 10.1089/10872910260196404] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
453 Negredo E, Ribalta J, Paredes R, Ferré R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L, Clotet B. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002;16:1383-9. [PMID: 12131215 DOI: 10.1097/00002030-200207050-00010] [Cited by in Crossref: 78] [Cited by in F6Publishing: 85] [Article Influence: 3.7] [Reference Citation Analysis]
454 Rodriguez-Guardado A, Maradona JA, Carton JA, Asensi V. Triglyceride increase can predict lipodystrophy in HIV patients under highly active antiretroviral therapy. AIDS 2002;16:1434-6. [PMID: 12131227 DOI: 10.1097/00002030-200207050-00022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
455 Janneh O, Hoggard PG, Tjia JF, Jones SP, Khoo SH, Maher B, Back DJ, Pirmohamed M. Intracellular Disposition and Metabolic Effects of Zidovudine, Stavudine and Four Protease Inhibitors in Cultured Adipocytes. Antiviral Therapy 2003;8:417-26. [DOI: 10.1177/135965350300800509] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
456 Encinas de la Iglesia J, Pérez García M, Fuertes Martín A. Efectos secundarios de los fármacos antirretrovirales. FMC - Formación Médica Continuada en Atención Primaria 2002;9:343-349. [DOI: 10.1016/s1134-2072(02)75598-9] [Reference Citation Analysis]
457 Miró Ò, López S, Pedrol E, Rodríguez-santiago B, Martínez E, Soler A, Milinkovic A, Casademont J, Nunes V, Gatell JM, Cardellach F. Mitochondrial Dna Depletion and Respiratory Chain Enzyme Deficiencies are Present in Peripheral Blood Mononuclear Cells of HIV-Infected Patients with Haart-Related Lipodystrophy. Antiviral Therapy 2003;8:333-8. [DOI: 10.1177/135965350300800410] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
458 Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA. Mitochondrial Proliferation, Dna Depletion and Adipocyte Differentiation in Subcutaneous Adipose Tissue of HIV-Positive Haart Recipients. Antiviral Therapy 2003;8:323-31. [DOI: 10.1177/135965350300800409] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
459 Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. Antiviral Therapy 2002;7:257-266. [DOI: 10.1177/135965350200700405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
460 van Heeswijk R, Veldkamp A, Mulder J, Meenhorst P, Lange J, Beijnen J, Hoetelmans R. Combination of Protease Inhibitors for the Treatment of HIV-1-Infected Patients: A Review of Pharmacokinetics and Clinical Experience. Antiviral Therapy 2002;6:201-229. [DOI: 10.1177/135965350200600401] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
461 Blanco Quintana F, García Benayas T, Soriano Vázquez V. [Lipodystrophy syndrome associated with the human immunodeficiency syndrome virus (I). General characteristics and etiopathogenesis]. Rev Clin Esp 2002;202:27-31. [PMID: 11940431 DOI: 10.1016/s0014-2565(02)70976-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
462 Seminari E, Tinelli C, Minoli L, Sacchi P, Filice G, Zocchetti C, Meneghetti G, Bruno R, Maserati R. Evaluation of the Risk Factors Associated with Lipodystrophy Development in a Cohort of HIV-Positive Patients. Antiviral Therapy 2002;7:175-180. [DOI: 10.1177/135965350200700306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
463 Wheat LJ, Farthing C, Cohen C, Pierone G, Lalezari J, Pilson RS, Siemon-hryczyk P, Baxter J, Beer V, Bellos NC, Bissett J, Braun J, Brosgart C, Burman W, Burnside A, Cervia J, Cheeseman S, Cimoch P, Cohen C, Dejesus E, Diaz L, Dieterich D, Dobkin J, Dretler R, El-sadr W, Eng R, Farthing C, Feinberg J, Feleke G, Fessel J, Fish D, Galpin J, Gathe J, Gilson I, Gold M, Goodgame J, Goodrich J, Greenberg R, Greiger P, Grossman H, Grossman R, Hanna B, Hathaway B, Hoffman-terry M, Jacobson S, Jemsek J, Jordan W, Kaplan M, Kostman J, Lalezari J, Landesman S, Lindquist C, Macarthur R, Madhava V, Marsh B, Martin D, Mathur-wagh U, Mcmeeking A, Miao P, Mogyoros M, Murphy R, Mustafa M, Nadler J, Norris D, Onbirbak B, Parker RH, Pearce D, Pierone G, Poblete R, Poretz DM, Reyelt MC, Rivera-vazquez C, Salvato P, Sands M, Schwartz R, Sension M, Skowron G, Slater L, Smith D, Stavola J, Steinhart C, Temesgen Z, Thompson M, Timpone J, Valentine FT, Vollmer K, Wada S, Ward D, Wheat LJ, Yangco B, Carey P, Jablonowski H, Theisen A, Lazzarin A, Ocana I, for the TIDBID (NR15520/M61018) study team (members listed in Appendix). Efficacy and Safety of Twice-Daily versus Three-Times Daily Saquinavir Soft Gelatin Capsules as Part of Triple Combination Therapy for HIV-1 Infection. Antiviral Therapy 2002;7:199-209. [DOI: 10.1177/135965350200700310] [Reference Citation Analysis]
464 Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F; NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002;16:569-77. [PMID: 11873000 DOI: 10.1097/00002030-200203080-00008] [Cited by in Crossref: 249] [Cited by in F6Publishing: 257] [Article Influence: 11.9] [Reference Citation Analysis]
465 Cohen OJ, Fauci AS. Current strategies in the treatment of HIV infection. Disease-a-Month 2002;48:A3-184. [DOI: 10.1067/mda.2002.124659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
466 Serghides L, Nathoo S, Walmsley S, Kain KC. CD36 deficiency induced by antiretroviral therapy. AIDS 2002;16:353-8. [PMID: 11834946 DOI: 10.1097/00002030-200202150-00006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
467 Hirschel B, Flepp M, Bucher HC, Zellweger C, Telenti A, Wagels T, Bernasconi E, Ledergerber B; Swiss HIV Cohort. Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. AIDS 2002;16:381-5. [PMID: 11834949 DOI: 10.1097/00002030-200202150-00009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
468 Walker UA, Brinkman K. NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction? HIV Med 2001;2:163-5. [PMID: 11737396 DOI: 10.1046/j.1464-2662.2001.00073.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
469 Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2001;2:174-80. [PMID: 11737398 DOI: 10.1046/j.1468-1293.2001.00073.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 3.0] [Reference Citation Analysis]
470 Justice AC, Landefeld CS, Asch SM, Gifford AL, Whalen CC, Covinsky KE. Justification for a new cohort study of people aging with and without HIV infection. J Clin Epidemiol 2001;54 Suppl 1:S3-8. [PMID: 11750202 DOI: 10.1016/s0895-4356(01)00440-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 1.7] [Reference Citation Analysis]
471 Mauss S, Schmutz G. L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome. HIV Med 2001;2:59-60. [PMID: 11737377 DOI: 10.1046/j.1468-1293.2001.00049.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
472 Sabin CA. The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. AIDS 2002;16 Suppl 4:S61-8. [PMID: 12699001 DOI: 10.1097/00002030-200216004-00009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 1.5] [Reference Citation Analysis]
473 Holodniy M, Miller V. Human Immunodeficiency Virus. Practical Guidelines in Antiviral Therapy 2002. [DOI: 10.1016/b978-044450884-3/50005-2] [Reference Citation Analysis]
474 Piketty C, Jayle D, Gonzalez-canali G, Debuire B, Baulieu E, Kazatchkine M. Low plasma levels of dehydroepiandrosterone (DHEA) and incidence of lipodystrophy: DHEA and lipodystrophy. HIV Medicine 2001;2:136-8. [DOI: 10.1046/j.1468-1293.2001.002002136.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
475 Thiébaut R, Dequae-merchadou L, Ekouevi D, Mercié P, Malvy D, Neau D, Dabis F, The Groupe d'Epidémiologie Clinique. Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-99: Hypertriglyceridaemia, antiretrovirals and HIV infection. HIV Medicine 2001;2:84-8. [DOI: 10.1046/j.1468-1293.2001.00057.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
476 Stears AJ, Byrne CD. Adipocyte metabolism and the metabolic syndrome: Adipocyte metabolism and the metabolic syndrome. Diabetes, Obesity and Metabolism 2001;3:129-42. [DOI: 10.1046/j.1463-1326.2001.00151.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
477 Duran S, Savès M, Spire B, Cailleton V, Sobel A, Carrieri P, Salmon D, Moatti JP, Leport C; APROCO Study Group. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001;15:2441-4. [PMID: 11740195 DOI: 10.1097/00002030-200112070-00012] [Cited by in Crossref: 221] [Cited by in F6Publishing: 192] [Article Influence: 10.0] [Reference Citation Analysis]
478 Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulli A, Chiumello G, di Natale B, Viganò A. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001;15:2415-22. [PMID: 11740192 DOI: 10.1097/00002030-200112070-00009] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 3.1] [Reference Citation Analysis]
479 Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, Larder B, Dewar RL, Fox CH, Hallahan CW, Justement JS, Migueles SA, Metcalf JA, Davey RT, Daucher M, Pandya P, Baseler M, Ward DJ, Fauci AS. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A 2001;98:15161-6. [PMID: 11734634 DOI: 10.1073/pnas.261568398] [Cited by in Crossref: 103] [Cited by in F6Publishing: 127] [Article Influence: 4.7] [Reference Citation Analysis]
480 Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001;15:2251-7. [PMID: 11698698 DOI: 10.1097/00002030-200111230-00006] [Cited by in Crossref: 86] [Cited by in F6Publishing: 87] [Article Influence: 3.9] [Reference Citation Analysis]
481 Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL, Eckel RH. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001;15:1993-2000. [PMID: 11600828 DOI: 10.1097/00002030-200110190-00012] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 3.4] [Reference Citation Analysis]
482 Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. AIDS 2001;15:1917-30. [PMID: 11600819 DOI: 10.1097/00002030-200110190-00003] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 2.8] [Reference Citation Analysis]
483 Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V, Dube MP. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001;15:2001-10. [PMID: 11600829 DOI: 10.1097/00002030-200110190-00013] [Cited by in Crossref: 78] [Cited by in F6Publishing: 84] [Article Influence: 3.5] [Reference Citation Analysis]
484 Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 2001;24:443-56. [PMID: 11368251 DOI: 10.2165/00002018-200124060-00003] [Cited by in Crossref: 74] [Cited by in F6Publishing: 79] [Article Influence: 3.4] [Reference Citation Analysis]
485 Kanamoto T, Kashiwada Y, Kanbara K, Gotoh K, Yoshimori M, Goto T, Sano K, Nakashima H. Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 2001;45:1225-30. [PMID: 11257038 DOI: 10.1128/AAC.45.4.1225-1230.2001] [Cited by in Crossref: 95] [Cited by in F6Publishing: 98] [Article Influence: 4.3] [Reference Citation Analysis]
486 Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN, Studd JW, Johnson MA. Reduced bone mineral density in HIV-positive individuals. AIDS 2001;15:1731-3. [PMID: 11546951 DOI: 10.1097/00002030-200109070-00019] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 4.2] [Reference Citation Analysis]
487 Keithley JK. CONTINUING EDUCATION OFFERING. Journal of the Association of Nurses in AIDS Care 2001;12:67-74. [DOI: 10.1016/s1055-3290(06)60160-x] [Reference Citation Analysis]
488 Shahmanesh M, Jaleel H, DeSilva Y, Ross JD, Caslake M, Cramb R. Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype. Sex Transm Infect 2001;77:283-6. [PMID: 11463929 DOI: 10.1136/sti.77.4.283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
489 Melvin AJ, Lennon S, Mohan KM, Purnell JQ. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses 2001;17:1117-23. [PMID: 11522181 DOI: 10.1089/088922201316912727] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 2.2] [Reference Citation Analysis]
490 Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 2001;6:14-20. [PMID: 11293802 DOI: 10.1046/j.1529-8027.2001.006001014.x] [Cited by in Crossref: 155] [Cited by in F6Publishing: 163] [Article Influence: 7.0] [Reference Citation Analysis]
491 Chang KH, Kim JM. Characteristics of HIV infection/AIDS in Korea. Korean J Intern Med 2001;16:1-7. [PMID: 11417298 DOI: 10.3904/kjim.2001.16.1.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
492 &NA;. The aetiology of antiretroviral-associated lipodystrophy remains elusive posing problems for its prevention and treatment. Drugs & Therapy Perspectives 2001;17:11-15. [DOI: 10.2165/00042310-200117130-00004] [Reference Citation Analysis]
493 García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F29-40. [PMID: 11416735 DOI: 10.1097/00002030-200106150-00002] [Cited by in Crossref: 143] [Cited by in F6Publishing: 147] [Article Influence: 6.5] [Reference Citation Analysis]
494 Ruiz L, Carcelain G, Martínez-Picado J, Frost S, Marfil S, Paredes R, Romeu J, Ferrer E, Morales-Lopetegi K, Autran B, Clotet B. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F19-27. [PMID: 11416734 DOI: 10.1097/00002030-200106150-00001] [Cited by in Crossref: 121] [Cited by in F6Publishing: 121] [Article Influence: 5.5] [Reference Citation Analysis]
495 Castetbon K, Anglaret X, Attia A, Toure S, Dakoury-Dogbo N, Messou E, N'Dri-Yoman T, Dabis F, Salamon R; Cotrimo-CL Study Group. Effect of early chemoprophylaxis with co-trimoxazole on nutritional status evolution in HIV-1-infected adults in Abidjan, Côte d'Ivoire. AIDS 2001;15:869-76. [PMID: 11399959 DOI: 10.1097/00002030-200105040-00007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
496 van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA; Prometheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001;15:847-55. [PMID: 11399957 DOI: 10.1097/00002030-200105040-00005] [Cited by in Crossref: 121] [Cited by in F6Publishing: 126] [Article Influence: 5.5] [Reference Citation Analysis]
497 Chastain MA, Chastain JB, Coleman WP. HIV Lipodystrophy. Dermatologic Surgery 2001;27:497-500. [DOI: 10.1097/00042728-200105000-00017] [Reference Citation Analysis]
498 Cirelli A, Cirelli G, Scavalli AS, Masciangelo R, Marini M. Dual-Energy x-ray absorptiometry in the early diagnosis of body shape changes in patients with HIV infection treated with nucleoside reverse transcriptase inhibitors and naive to protease inhibitors. Current Therapeutic Research 2001;62:386-393. [DOI: 10.1016/s0011-393x(01)89003-2] [Reference Citation Analysis]
499 Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, Rieger A, Wagner OF, Quehenberger P. Sex differences in HAART-associated dyslipidaemia. AIDS 2001;15:725-34. [PMID: 11371687 DOI: 10.1097/00002030-200104130-00008] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 2.9] [Reference Citation Analysis]
500 Dukers NH, Stolte IG, Albrecht N, Coutinho RA, de Wit JB. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men. AIDS 2001;15:812-3. [PMID: 11371704 DOI: 10.1097/00002030-200104130-00025] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 2.0] [Reference Citation Analysis]
501 Mastroianni CM, d'Ettorre G, Forcina G, Lichtner M, Corpolongo A, Coletta S, Vullo V. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS 2001;15:820-1. [PMID: 11371708 DOI: 10.1097/00002030-200104130-00029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.1] [Reference Citation Analysis]
502 Tebas P, Henry K, Nease R, Murphy R, Phair J, Powderly WG. Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. AIDS 2001;15:591-9. [PMID: 11316996 DOI: 10.1097/00002030-200103300-00008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
503 Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, Riesen W, Nicod P, Darioli R, Telenti A, Mooser V; Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy. AIDS 2001;15:329-34. [PMID: 11273212 DOI: 10.1097/00002030-200102160-00005] [Cited by in Crossref: 192] [Cited by in F6Publishing: 203] [Article Influence: 8.7] [Reference Citation Analysis]
504 Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J, Barberá M, Santín M, Gudiol F, Hidalgo M, Knobel H, Azuaje C, Ribera E, Roget M, Force L, Dalmau D, Suarez C; the Combine Study Team (members listed in Appendix). A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study). Antiviral Therapy 2002;7:81-90. [DOI: 10.1177/135965350200700202] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
505 Bucy RP, Kilby JM. Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics? AIDS 2001;15 Suppl 2:S36-42. [PMID: 11424975 DOI: 10.1097/00002030-200102002-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
506 Gharakhanian S. The HIV-associated lipodystrophy syndrome: research, results, yet more questions. AIDS 2001;15:271-3. [PMID: 11216938 DOI: 10.1097/00002030-200101260-00019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
507 Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, Montanera JS. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231-9. [PMID: 11216932 DOI: 10.1097/00002030-200101260-00013] [Cited by in Crossref: 182] [Cited by in F6Publishing: 192] [Article Influence: 8.3] [Reference Citation Analysis]
508 Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, Tyrer M, Chaloner C, Wilson D, Loveday C, Johnson MA, Phillips AN. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001;15:185-94. [PMID: 11216926 DOI: 10.1097/00002030-200101260-00007] [Cited by in Crossref: 157] [Cited by in F6Publishing: 160] [Article Influence: 7.1] [Reference Citation Analysis]
509 Mercié P, Viallard JF, Thiébaut R, Faure I, Rispal P, Leng B, Pellegrin JL. Efavirenz-associated breast hypertrophy in HIV-infection patients. AIDS 2001;15:126-9. [PMID: 11192857 DOI: 10.1097/00002030-200101050-00021] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
510 Figgitt DP, Plosker GL. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection. Drugs 2000;60:481-516. [PMID: 10983742 DOI: 10.2165/00003495-200060020-00016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
511 David MH, Fichtenbaum CJ. The Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus Infection. Infectious Diseases in Clinical Practice 2001;10:7-13. [DOI: 10.1097/00019048-200101000-00003] [Reference Citation Analysis]
512 Egger M, Junghans C, Friis-Møller N, Lundgren JD. Highly active antiretroviral therapy and coronary heart disease: the need for perspective. AIDS 2001;15 Suppl 5:S193-201. [PMID: 11816168 DOI: 10.1097/00002030-200100005-00023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
513 John M, Nolan D, Mallal S. Antiretroviral Therapy and the Lipodystrophy Syndrome. Antiviral Therapy 2001;6:9-20. [DOI: 10.1177/135965350100600102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
514 Weiel JE, Lenhard JM. Chapter 13. In vitro and in vivo approaches to studying antiretroviral therapy (ART)-induced metabolic complications. Annual Reports in Medicinal Chemistry 2001. [DOI: 10.1016/s0065-7743(01)36053-0] [Reference Citation Analysis]
515 Mildvan D. Rationale and Strategies for Antiretroviral Therapy in HIV-1 Infection. Atlas of AIDS 2001. [DOI: 10.1007/978-1-4757-4549-8_19] [Reference Citation Analysis]
516 Kaufmann GR, Zaunders JJ, Cunningham P, Kelleher AD, Grey P, Smith D, Carr A, Cooper DA. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000;14:2643-51. [PMID: 11125882 DOI: 10.1097/00002030-200012010-00003] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 3.3] [Reference Citation Analysis]
517 Kanmaz TJ, Lee NJ. Significant Toxicities Associated with Antiretroviral Therapy. Journal of Pharmacy Practice 2000;13:457-474. [DOI: 10.1106/2uu8-8jjd-uhru-c14r] [Reference Citation Analysis]
518 Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf. 2000;23:57-76. [PMID: 10915032 DOI: 10.2165/00002018-200023010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
519 Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 2000;23:57-76. [PMID: 10915032 DOI: 10.2165/00002018-200023010-00004] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 3.3] [Reference Citation Analysis]
520 Nguyen AT, Gagnon A, Angel JB, Sorisky A. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS 2000;14:2467-73. [PMID: 11101056 DOI: 10.1097/00002030-200011100-00007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 2.5] [Reference Citation Analysis]
521 García F, Knobel H, Sambeat MA, Arrizabalaga J, Aranda M, Romeu J, Dalmau D, Segura F, Gomez-Sirvent JL, Ferrer E, Cruceta A, Gallart T, Pumarola T, Miró JM, Gatell JM; Spanish SCAN Study Group. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. AIDS 2000;14:2485-94. [PMID: 11101059 DOI: 10.1097/00002030-200011100-00010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 1.5] [Reference Citation Analysis]
522 Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, Perilli F, Lillo A, Ferraro S, Gargiulo M, Chirianni A, Angarano G, Regina G, Pastore G. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000;14:F123-8. [PMID: 11101050 DOI: 10.1097/00002030-200011100-00001] [Cited by in Crossref: 152] [Cited by in F6Publishing: 167] [Article Influence: 6.6] [Reference Citation Analysis]
523 Rizzardi GP, Tambussi G, Bart PA, Chapuis AG, Lazzarin A, Pantaleo G. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. AIDS 2000;14:2257-63. [PMID: 11089613 DOI: 10.1097/00002030-200010200-00006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 1.5] [Reference Citation Analysis]
524 Jaquet D, Lévine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, Lévy-Marchal C. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000;14:2123-8. [PMID: 11061653 DOI: 10.1097/00002030-200009290-00008] [Cited by in Crossref: 136] [Cited by in F6Publishing: 138] [Article Influence: 5.9] [Reference Citation Analysis]
525 Wintergerst U, Kurowski M, Rolinski B, Müller M, Wolf E, Jaeger H, Belohradsky BH. Use of saliva specimens for monitoring indinavir therapy in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2000;44:2572-4. [PMID: 10952622 DOI: 10.1128/AAC.44.9.2572-2574.2000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
526 Muir Bowers J. Lipodystrophy. Nutrition and AIDS, Second Edition 2000. [DOI: 10.1201/9781420042290.ch10] [Reference Citation Analysis]
527 Hatano H, Miller KD, Yoder CP, Yanovski JA, Sebring NG, Jones EC, Davey RT Jr. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 2000;14:1935-42. [PMID: 10997397 DOI: 10.1097/00002030-200009080-00008] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 2.4] [Reference Citation Analysis]
528 Sav??s M, Ch??ne G, Suissa S. Lipodystrophy and Nucleoside Analogue Therapy in HIV-Infected Patients: Important Questions, Few Valid Answers. Journal of Acquired Immune Deficiency Syndromes 2000. [DOI: 10.1097/00042560-200009010-00016] [Reference Citation Analysis]
529 Orenstein JM, Bhat N, Yoder C, Fox C, Polis MA, Metcalf JA, Kovacs JA, Falloon J, Walker RE, Masur H, Lane HC, Davey RT. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression. AIDS 2000;14:1709-15. [PMID: 10985306 DOI: 10.1097/00002030-200008180-00004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 1.5] [Reference Citation Analysis]
530 Behrens GM, Lloyd D, Schmidt HH, Schmidt RE, Trembath RC. Lessons from lipodystrophy: LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophy. AIDS 2000;14:1854-5. [PMID: 10985325 DOI: 10.1097/00002030-200008180-00023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
531 Abourjaily P, Small F. HIV‐Associated Disorders in Fat Distribution and Lipid Metabolism. Nutrition in Clinical Care 2000;3:237-243. [DOI: 10.1046/j.1523-5408.2000.00058.x] [Reference Citation Analysis]
532 Katlama C, Tubiana R. Les traitements antirétroviraux. Annales de l'Institut Pasteur / Actualités 2000;11:23-37. [DOI: 10.1016/s0924-4204(00)80024-4] [Reference Citation Analysis]
533 Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S, Cooper DA. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 2000;14:1171-80. [PMID: 10894281 DOI: 10.1097/00002030-200006160-00014] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 3.0] [Reference Citation Analysis]
534 Sabin CA, Yee TT, Devereux H, Griffioen A, Loveday C, Phillips AN, Lee CA. Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy. AIDS 2000;14:1001-7. [PMID: 10853982 DOI: 10.1097/00002030-200005260-00012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
535 Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, González-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12. [PMID: 10839588 DOI: 10.1097/00002030-200005050-00006] [Cited by in Crossref: 120] [Cited by in F6Publishing: 121] [Article Influence: 5.2] [Reference Citation Analysis]
536 Pett SL, Milliken S. Current review of the metabolic and endocrine disturbances in human immunodeficiency virus infection: . Current Opinion in Endocrinology & Diabetes 2000;7:96-101. [DOI: 10.1097/00060793-200004000-00009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
537 Forsyth BW. HIV Infection in Children: A New Hope. Child and Adolescent Psychiatric Clinics of North America 2000;9:279-94. [DOI: 10.1016/s1056-4993(18)30119-6] [Reference Citation Analysis]
538 Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63-7. [PMID: 10770534 DOI: 10.1097/00002030-200003100-00005] [Cited by in Crossref: 389] [Cited by in F6Publishing: 402] [Article Influence: 16.9] [Reference Citation Analysis]
539 Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 1999;58:1165-203. [PMID: 10651394 DOI: 10.2165/00003495-199958060-00011] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 2.8] [Reference Citation Analysis]
540 Hengge UR, Exner V, Esser S, Rudel HP, Müller K, Goos M. Effektivität, Verträglichkeit und Sicherheit einer Kombinationstherapie mit Stavudin, Didanosin und Nelfinavir in naiven vs. vorbehandelten HIV-Patienten: 18 Monatsdaten. HIV-Infekt 2000. [DOI: 10.1007/978-3-642-59683-4_40] [Reference Citation Analysis]
541 Behrens G, Schmidt HH, Genschel J, Stoll M, Dejam A, Haas R, Manns MP, Schmidt RE. Veränderungen des Lipidstoffwechsels bei HIV-Patienten unter der Therapie mit Proteaseinhibitoren. HIV-Infekt 2000. [DOI: 10.1007/978-3-642-59683-4_62] [Reference Citation Analysis]
542 Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-505. [PMID: 10630518 DOI: 10.1097/00002030-199912240-00002] [Cited by in Crossref: 295] [Cited by in F6Publishing: 253] [Article Influence: 12.3] [Reference Citation Analysis]